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ABSTRACT
MATTHEW JAMES HIGGINS: Regulation of Human Cytidine Triphosphate Synthetase 1
by Phosphorylation and Interacting Proteins
(Under the direction of Dr. Lee M Graves)
CTP is essential for the synthesis of phospholipids, DNA/RNA and the sialylation of
proteins. Of the two pathways known to synthesize CTP (de novo and salvage), the de novo
synthesis pathway is thought to be the key regulator of CTP pool size in mammalian cells.
CTPS is the rate-limiting enzyme in the de novo synthesis of CTP. CTPS catalyzes the
amination of UTP to form CTP using glutamine as the amine donor and GTP as an allosteric
activator. ATP is hydrolyzed in the process and CTP is a feedback inhibitor. In S. cerevisiae
CTP synthetase (CTPS) is regulated by phosphorylation by PKA and PKC. The goals of this
study were to investigate phosphorylation regulation of mammalian CTPS1 and elucidate
CTPS1 interacting proteins. PKA or PKC were found not to be involved in the
phosphorylation of CTPS1 in intact HEK 293 cells. However, endogenous human CTPS1
was phosphorylated under low-serum conditions in a GSK3-dependent manner. S571 was
identified as the major GSK3 phosphorylation site and S574 and S575 were also identified as
phosphorylation sites. GSK3 phosphorylation of human CTPS1 decreased enzyme activity
and in vitro dephosphorylation increased CTPS1 activity indicating that phosphorylation
suppresses CTPS1 activity. CK I was also found to be involved in the phosphorylation of
CTPS1. CK I inhibition did not affect CTPS1 activity indicating that CK I may regulate
another function of CTPS1. Investigation of CTPS1 interacting proteins revealed that the
iv
peptidylprolyl isomerase, Pin1, can interact with CTPS1 in a S575 phosphorylation-
dependent manner. However, reduction of Pin1 expression did not affect CTPS1 activity
suggesting that the regulation of CTPS1 by Pin1 may be through another mechanism.
Continued investigation of CTPS1 interacting proteins revealed, among other proteins,
tubulin as a CTPS1 interacting proteins. Further investigation is needed to understand the
significance of this interaction. CTPS1 expression was found to be highest in the brain
suggesting CTPS1 may have a brain-specific function. This study is the first to characterize
the phosphorylation regulation of mammalian CTPS1 expressed in mammalian cells and
elucidate CTPS1 interacting proteins and CTPS1 expression in mammalian tissue.
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1. Introduction
1.1 CTPS Background
1.1.1 Discovery and History of CTPS
In 1956, Irving Lieberman reported that a partially purified bacteria extract catalyzed
the amination of UTP to form CTP. The substrates required for the reaction were Mg2+,
UTP, NH3, ATP and the products formed were CTP, ADP, and Pi (Lieberman, 1956).
However evidence accumulated several years after this finding suggesting that glutamine is
the source for the amination of UTP to form CTP. In particular, Edwin Sebrings group using
15N labeled glutamine and 15N labeled NH4Cl demonstrated that the preferred source for the
labeling of the cytosine ring in mammalian cells was glutamine and not NH4Cl (Salzman et
al., 1958). It was later suggested that the purification of the bacterial extract done by
Lieberman et al. had inactivated the glutaminase activity of the enzyme, not allowing
glutamine to serve as the amine donor and thus requiring NH3 as a substrate. Around this
same time Kammen and Hurlbert showed in lysates from rat hepatomas that low levels of
guanosine nucleotides stimulated the conversion of uridine nucleotides to cytidine
nucleotides two to three fold. In this same manuscript Kammen and Hurlbert also
demonstrated that cytidine nucleotides had an inhibitory effect on the conversion of uridine
nucleotides to cytidine nucleotides (Kammen and Hurlbert, 1958). Coupling these
2observations with the original reaction proposed by Lieberman, produced a reaction where
UTP, glutamine or NH3, ATP, Mg2+ were required to form CTP and guanosine nucleotides
stimulated the reaction and cytidine nucleotides, the reaction product(s), inhibited the
reaction (Figure 1.1). The 300 fold purification of CTPS by Long and Pardee in 1967
allowed for the first kinetic studies of CTPS and revealed that GTP was the primary
guanosine nucleotide involved in the stimulation of the reaction and CTP as the primary
cytidine nucleotide involved in the feedback inhibition of the enzyme when substrates are at
saturating concentrations (Long and Pardee, 1967).
With the advent of the molecular biology era it was possible to identify the genes
encoding CTPS. The first mammalian CTPS gene, CTPS1, was identified by functional
complementation of a cytidine auxotroph cell line with purified human metaphase
chromosomes and was mapped to human chromosome 1 (Yamauchi et al., 1990). Since it
was shown that the yeast genome encoded for two CTPS enzymes, van Kuilenburg et al.
screened the NCBI database for a second CTPS isoenzyme, CTPS2, and identified an EST
clone derived from colon tumor which was 74% identical to CTPS1 and mapped CTPS2 to
the X chromosome (van Kuilenburg et al., 2000a; van Kuilenburg et al., 2000b).
1.1.2 Regulation of CTPS by Tetramerization
Initially, active CTPS was thought to exist as a dimer, because the molecular weight
of the enzyme would double under certain conditions. Further investigation using CTPS
purified from bacteria revealed that the doubling in molecular weight was due to the
dimerization of dimers and not dimerization of monomers and that the isolated CTPS
strongly associated as dimers and would form a tetramer when it was enzymatically active.
3The minimum substrate requirement for purified E. coli CTPS to aggregate to the
tetramer molecular weight (tetramer = 210,000 MW, monomer = 52,000 MW) was the
presence of ATP, UTP and Mg2+ in the reaction mixture. UTP plus Mg2+ or ATP plus Mg2+
were not sufficient to cause aggregation to the tetramer molecular weight and NaCl
concentrations up to 0.5 M did not alter the tetramerization of purified E. coli CTPS. Only
under denaturing conditions (e.g. 6 M guanidine, 8 M urea or 60% formic acid) was the
monomer observed, under all other conditions CTPS existed as a dimer or tetramer (Long et
al., 1970). Unlike the tetramerization of E. coli CTPS, the tetramerization of Lactococcus
lactis CTPS was found to coordinately decrease with higher concentrations of salt (NH4Cl or
KCl) suggesting that the influence of salt on oligomerization of CTPS my be species specific
(Willemoes and Larsen, 2003).
The first investigation of the size and polymerization of mammalian CTPS was done
by McPartland and Weinfeld in 1976 who found that CTPS purified from bovine liver
existed as a 130,000 molecular weight enzyme in the absence of nucleotides and a 260,000
molecular weight protein in the presence of UTP, ATP and GTP. UTP and ATP were
absolutely required for the formation of the 260,000 MW species (Long et al., 1970). In
1988, CTPS was purified 31,000 fold from rat liver cytosol and by HPLC and SDS-PAGE
analysis mammalian CTPS was found to exist as a monomer (66,000 MW), dimer (120,000
MW) and a tetramer (240,000 MW). Incubation of the dimer with UTP, ATP and MgCl2
were found to be the optimum conditions by which the dimer formed the tetramer
recapitulating the conditions by which the bacterial CTPS also formed a tetramer (Thomas et
al., 1988).
4Investigation of CTPS tetramer formation from Saccharomyces cerevisiae (S.
cerevisiae) revealed a requirement for ATP, UTP and MgCl2 consistent with the conditions
for CTPS tetramer formation in bacteria and mammals. However, elimination of ATP did
not entirely inhibit tetramer formation suggesting that ATP facilitates but is not required for
tetramer formation in S. cerevisiae. Furthermore, using the non-hydrolyzable ATP analog,
AMP-PNP, the tetramer formation in S. cerevisiae was inhibited demonstrating that ATP
needs to be hydrolyzed for ATP to fully enhance tetramerization. Elimination of UTP
completely inhibited tetramerization demonstrating the requirement for UTP in CTPS
tetramerization. Tetramerization of CTPS in the presence of saturating concentrations of
ATP and UTP was not affected by varying protein concentration from 0.1 to 1 mg/ml
(Pappas et al., 1998).
1.1.3 Feedback Regulation of CTPS
Feedback inhibition is a common mode for regulating enzymes. CTPS generates
three products; glutamate, ADP and CTP. Glutamate, the product formed from the
deamination of glutamine, was not observed to inhibit calf liver purified CTPS when the
concentrations of UTP, ATP or glutamine were varied.
5Figure 1.1 CTPS Reaction Mechanism
Blue arrow designates site on UTP pyrimidine ring where amine is exchanged.
Glutamine is the amine donor that gets attached to 4 position on UTP to form CTP. CTP is a
feedback inhibitor and GTP allosterically activates CTPS. ADP and glutamate are
byproducts of the CTPS reaction.
6ADP, the product of ATP hydrolysis, showed mixed (competitive and non-competitive)
inhibition with respect to ATP and UTP, but uncompetitive inhibition with respect to
glutamine which led to the suggestion that ADP may need to be released from the enzyme
before UTP or glutamine can bind (McPartland and Weinfeld, 1979).
As observed with other enzymes, the major product of the CTPS reaction, CTP, can
feedback inhibit CTPS. In CTPS purified from E. coli, CTP was found to be a competitive
inhibitor with respect to UTP when ATP concentrations were saturating and a non-
competitive inhibitor with respect to ATP when concentrations of UTP were saturating. CTP
inhibition was observed when either NH3 or glutamine served as amine donors. When
glutamine was used as the amine donor and the concentrations of UTP or ATP are non-
saturating, CTP (0.3 mM) also acted as an inhibitor and did not markedly affect the
cooperative binding of ATP or UTP. When NH3 was used as the amine donor and the
concentrations of UTP or ATP were non-saturating, CTP (0.3 mM) was activating and
reduced the cooperative binding of both UTP and ATP. The addition of CTP in the NH3
reaction changed the sigmoidal kinetics of UTP and ATP to Michaelis kinetics. At higher
concentrations of CTP in the NH3 reaction CTP was found to be less activating and
eventually inhibitory (Long and Pardee, 1967). The ability of CTP to activate the CTPS
reaction under conditions where substrates are not saturating is thought to insure basal
synthesis of CTP.
Investigation of CTP inhibition of CTPS purified from calf liver using glutamine as
the amine donor revealed that CTP showed mixed (competitive and non-competitive)
inhibition with respect to glutamine and ATP. CTP inhibition with respect to UTP shifted
7the kinetics from Michaelis kinetics to sigmoidal kinetics suggesting increased cooperativity
in the presence of CTP. Similar to what was observed with the bacterial CTPS, lower
concentrations of CTP (0-0.4 mM) were activating and higher concentrations were
inhibitory. In contrast to CTP, 3-deaza UTP, a competitive inhibitor with respect to UTP,
showed inhibition at all concentrations. CTP did not alter the oligomerization of purified calf
liver CTPS further demonstrating that CTP feedback inhibition of CTPS does not involve
dissociation of the CTPS tetramer (McPartland and Weinfeld, 1979).
Analysis of CTP feedback inhibition in S. cerevisiae demonstrated that, like
mammalian CTPS, yeast CTPS was inhibited by CTP with respect to UTP and the presence
of CTP increased the cooperativity with respect to UTP. CTP decreased the apparent Vmax
and increased the apparent Km for UTP (Yang et al., 1994). CTP also did not prevent
tetramerization of CTPS demonstrating that the mechanism by which CTP inhibits CTPS
does not involve inhibiting tetramerization (Pappas et al., 1998; Yang et al., 1994).
1.1.4 GTP Regulation of CTPS
One of the first observations that guanosine nucleotides, including GTP, could
positively regulate CTPS was published in 1960 by Hurlbert and Kammen who found that
CTPS, purified from Novikoff transplantable hepatoma cells, could be stimulated by
guanosine nucleotides and that GTP could stimulate the amination activity of CTPS up to
500% (Hurlbert and Kammen, 1960). Using CTPS purified from E. coli, GTP at non-
saturating concentrations was not found to cause cooperative binding with respect to UTP
suggesting that GTP, unlike ATP at non-saturating concentrations, did not influence UTP
binding and the effect of GTP on CTPS activity was most likely not by altering UTP binding
8(Long and Pardee, 1967). Further investigation by another group also using purified bacteria
CTPS found that GTP enhanced the negative cooperativity with respect to glutamine when
the concentration of GTP was progressively decreased below the saturating concentration of
GTP implicating GTP in regulating the glutaminase half of the CTPS reaction and not the
half involving ATP and UTP (Levitzki and Koshland, 1969). UTP or ATP binding
cooperativity was not observed with CTPS purified from bovine liver when the concentration
of GTP was varied, suggesting that in mammalian CTPS, as in bacterial CTPS, GTP does not
increase CTPS activity by influencing ATP or UTP binding (Savage and Weinfeld, 1970).
With evidence accumulating that GTP was not affecting the ATP and UTP half of the CTPS
reaction, future investigations focused on the glutamine half of the reaction. DON, the
glutamine transition state analog, reacts with one of the two subunits of the CTPS dimer and
the presence of saturating concentrations of GTP increased the reaction rate up to eight fold.
When saturating concentrations of GTP were added to the CTPS tetramer, formed by
addition of UTP and ATP, the rate of reaction with DON was still increased eight fold, as
was observed with the GTP and the CTPS dimer, but the negative cooperativity of the DON
reaction with the tetramer was abolished (Levitzki et al., 1971).
A thorough analysis of the allosteric effect of GTP on CTPS activity was done using
non-hydrolyzable ATP analogs (ADPNP, ADPCH2P) which inhibits the ATP and UTP
reaction, but allow the glutaminase reaction to proceed. Using ADPNP, GTP activated the
glutaminase activity (increase in kcat, increase in the turnover of molecules) to the same
extent as with ATP. The increase in turnover number (kcat) of the glutaminase reaction using
the tetramer was appreciably higher than that of the dimer and approximated the amount of
CTP formed suggesting that the NH3 is consumed as soon as it is formed. The glutaminase
9activity of CTPS is much less than the activity of another glutaminase that had been
investigated (CTPS kcat = 290 sec-1, glutaminase kcat = 38,000 sec-1) further suggesting that
the glutaminase activity in CTPS is there for providing NH3 for the formation of CTP and not
a general cellular glutaminase. Binding of GTP at 25°C to CTPS in the presence of UTP
and ADPCH2P or in the presence of UTP and ATP with DON labeled CTPS showed distinct
negative cooperativity indicating that under conditions where the formation of the tetramer is
favored, GTP binding negatively influences further binding of another GTP molecule.
However, GTP binding to DON-labeled CTPS in the presence of UTP and ATP at 4°C
showed positive cooperativity indicating that temperature can influence GTP binding. GTP
binding to the dimer at 25°C was found to be independent, not cooperative, and GTP bound
to two sites in the dimer. The allosteric effect of GTP on CTPS activity when NH3 was used
as the substrate instead of glutamine showed that GTP inhibited the NH3 activity of CTPS
only when CTPS was labeled with DON otherwise GTP had no effect on CTPS when NH3
was used as a substrate (Levitzki and Koshland, 1972).
Characterization of GTP regulation of S. cerevisiae CTPS revealed that GTP was not
an absolute requirement for CTPS activity, but GTP did stimulate activity four fold.
Negative cooperativity was observed with respect to both glutamine and GTP, especially at
lower concentrations consistent with what has been observed before (Levitzki and Koshland,
1969) (Yang et al., 1994). Investigation of human CTPS partially purified from a leukemia
cell line, HL60, demonstrated that GTP showed slight positive cooperativity in the presence
of saturating concentrations of UTP and ATP (Van Kuilenburg et al., 1998).
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The most recent biochemical investigation of how GTP affects CTPS activity was
done using CTPS purified from L. lactis. To uncouple CTP synthesis from the glutaminase
activity the non-hydrolyzable ATP analog, ATPS, was used. In the presence of ATPS,
GTP can cause up to a six fold increase in kcat as measured by isothermal calorimetry (ITC),
but the Km for glutamine remained the same. This indicates that GTP increases the turnover
rate of the glutaminase reaction, but does not alter the affinity of CTPS for glutamine. At
GTP concentrations higher than 1 mM and UTP plus ATPS concentrations at 0.1 mM, GTP
was inhibitory and this inhibition disappeared when UTP plus ATPS concentrations were
increased to 1 mM suggesting UTP and possibly ATP binding influence the effect GTP has
on the glutaminase activity of CTPS. Coupling CTP synthesis with glutaminase activity by
substituting 1 mM ATP for 1 mM ATPS, resulted in GTP (1 mM) stimulating a 1.7 fold
increase in the kcat for hydrolysis of glutamine, but a forty-one fold increase in kcat for CTP
synthesis and a slight decrease in the Km for glutamine when compared to the absence of
GTP. Further investigation using 0.1 mM UTP and 0.1 mM ATP demonstrated only a seven
fold increase in kcat for CTP synthesis and a Ka value for GTP three orders of magnitude
lower than what was observed when the reactions were uncoupled (i.e. in the presence of
ATPS instead of ATP). Coupling of the CTP synthesis reaction with the glutaminase
reaction greatly enhances the ability of GTP to positively regulate CTPS. Indeed, the authors
found that in the absence of GTP, the glutamine hydrolysis rate was significantly higher than
the rate of CTP synthesis and the presence of GTP seemed to couple the glutaminase reaction
with CTP synthesis. Based upon the accumulation of data the authors suggest that the true
activator of the CTPS reaction is the fairly stable 4-phosphorylated UTP intermediate. Also,
as observed with E. coli CTPS, these authors observed that DON-labeled CTPS was inhibited
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by GTP when NH4Cl was used as a substrate. However, inhibition of L. lactis CTPS by GTP
showed negative cooperativity whereas the E. coli enzyme did not. These authors support a
model where GTP acts as a “lid” that functions to coordinate glutamine hydrolysis with the
formation of 4-phosphoryl UTP possibly by playing a role in the formation of the tunnel
whereby the liberated NH3 is passed to the active site containing the 4-phosphoryl-UTP
intermediate (Willemoes and Sigurskjold, 2002).
1.1.5 CTPS Reaction Mechanism
The elucidation that CTPS catalyzed the formation of CTP by aminating UTP using
glutamine as the preferred amine donor and hydrolyzing ATP in the process suggested CTPS
catalyzed two separate, but coordinately regulated reactions. The first reaction was the
liberation of NH3 from glutamine catalyzed by the glutaminase region of CTPS and the
second reaction was the hydrolysis of ATP which involved UTP.
1.1.5.1 Role of UTP and ATP
Early biochemical studies demonstrated that UTP concentrations could influence
ATP binding and ATP concentrations could influence UTP binding suggesting these two
substrates had interacting binding sites (Long and Pardee, 1967). To investigate whether a
phosphorylated UTP intermediate was formed, UTP was labeled with [18O] at the 4’ position
of the pyrimidine ring of UTP, the position of the pyrimidine ring on UTP that gets aminated
to form CTP, and used in a CTPS reaction. Pi containing [18O] was found as a product of the
reaction demonstrating that a 4’-phosphoryl UTP intermediate is formed (Levitzki and
Koshland, 1971). Since the exchange of ADP for ATP was very low (only ~1%) in the
absence of glutamine or ammonia and the exchange did not depend on UTP, and the nascent
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ammonia liberated from glutamine was thought to immediately react with UTP, the model
championed by many researchers at the time was that ammonia reacted with UTP to form a
NH2-UTP adduct that then reacted with ATP to form a H2PO4-NH2-UTP tetrahedral
intermediate. Since the phosphate molecule on the 4’ position is an excellent leaving group
and the tetrahedral intermediate is not very stable, CTP is formed in an almost irreversible
fashion (Koshland, 1974).
Using the positional isotope exchange (PIX) technique developed by Midelfort and
Rose, researchers revisited the investigation of intermediates in the CTPS reaction. Using
ATP labeled with [18O] at the - bridge position it was shown in the absence of ammonia
but in the presence of UTP and Mg2+ that UTP can be phosphorylated at the 4 position on the
pyrimidine ring of UTP (von der Saal et al., 1985a; von der Saal et al., 1985b). Furthermore,
the data suggested that ADP release occurred only after ammonia binding revealing that ADP
binds tightly to CTPS and could explain why the ATP-ADP exchange in the absence of
ammonia was not observed in the initial studies by Koshlands group. Using CTPS partially
purified from Ehrlich ascites tumor cells it was shown that in the absence of substrates ADP
is not formed, further demonstrating the requirement for all substrates being present before
ADP can be exchanged (Kizaki et al., 1985). Using rapid quench kinetics it was
demonstrated that GTP increases the rate of the steps of the reaction leading up to
intermediate formation and glutamine was also found to shift the internal equilibrium
towards the formation of the intermediate complex. Furthermore, in the absence of GTP data
was obtained, using isotope partitioning, suggesting that UTP dissociates from the enzyme
complex faster than it is used to form products. In the presence of GTP more of the enzyme-
UTP complex was formed suggesting GTP increases the rate of product formation relative to
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substrate dissociation. Combining the data from the rapid quench kinetic and isotope
partitioning experiments demonstrates that ATP phosphorylates UTP to generate a 4-
phosphoryl UTP intermediate and this intermediate plays a key role in determining the rate of
the CTPS reaction (Lewis and Villafranca, 1989).
1.1.5.2 Role of the Amine Donor, Glutamine
Ammonia can serve as the amine donor directly for the formation of CTP, but since
the concentrations of exogenous ammonia needed to achieve appreciable enzyme activity are
high, this is thought, for most organisms, not to be biologically relevant. Evidence soon after
the discovery of the CTPS reaction accumulated that glutamine seemed like the preferred
amine donor. In particular early work done by Salzman using [15N] labeled glutamine and
Eidinoff who found that the glutamine inhibitor, DON, inhibited the cytosine incorporation in
DNA and RNA provided the first evidence suggesting that glutamine serves as the amine
donor for the CTPS reaction (Eidinoff et al., 1958; Salzman et al., 1958). Many studies since
this seminal discovery have confirmed that glutamine is the preferred amine donor.
However, one study using CTPS partially purified from Chinese hamster fibroblasts has
found synergism between amine donors and also found that arginine can serve as an amine
donor (McLaren and Chu, 1983). The same synergy between amine donors and whether
arginine can serve as an amine donor has not been investigated in other organisms suggesting
glutamine may not be the only amine donor or that the hamster CTPS is biochemically
different from other CTPSs that have thus far been investigated.
The reaction that catalyzes the release of ammonia from glutamine occurs in the
glutaminase region of CTPS. Initial investigation of the number of glutamine binding sites in
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CTPS using [14C] labeled DON revealed one molecule of DON bound per CTPS dimer
(Long et al., 1970). A more thorough investigation found that CTPS reacts through a “Half-
of-the-Sites” reaction mechanism meaning that only half of the potential substrate binding
sites are occupied when substrates or inhibitors are at saturating concentrations (e.g. total
substrate binding sites = n , during substrate/inhibitor saturation only n/2 are occupied)
(Levitzki et al., 1971). GTP can affect DON binding, but at saturating concentrations of
DON the “Half-of-the-Sites” reaction mechanism is still observed.
The CTPS glutaminase domain belongs to the family of type I amidotransferases also
known as the triad type because they contain a cysteine-histidine-glutamate triad of amino
acid that catalyze glutamine hydrolysis. Other members of the triad type of
amidotransferases include anthranilate synthase, formylglycinamidine synthase, GMP
synthase, imidazole glycerol phosphate synthase and carbamoyl phosphate synthase (CPS)
(Mei and Zalkin, 1989; Zalkin, 1985; Zalkin, 1993). Mutation of the catalytic cysteine
(C379) in E. coli CTPS, identified by sequence alignment with other amidotransferases, to a
serine or alanine reduced the apparent Km and kcat of glutamine below detectable levels
whereas the ability of the enzyme to used exogenous ammonia was unchanged (Bearne et al.,
2001). The liberated ammonia molecule from glutamine hydrolysis travels down what is
known as an ammonia tunnel where it reacts with the 4-phosphoryl UTP to form CTP.
Limited proteolysis of the E. coli CTPS has identified that the amidotransferase domain
resides in the c-terminus of the enzyme (Simard et al., 2003).
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1.1.6 Structural Studies on CTPS
Thus far crystal structures from E. coli CTPS, Thermus thermophilus HB8 CTPS and
the synthetase domain (amidoligase domain) of human CTPS1 have been solved. These
structures have confirmed and clarified much of the biochemical evidence that has
accumulated over the preceding half a century.
1.1.6.1 CTPS Oligomerization
The first published crystal structure of CTPS was that of E. coli CTPS without any
ligands bound, apo CTPS. The high concentration of CTPS used for the crystallization
induced tetramerization of CTPS allowing for the analysis of what residues are involved in
both dimer and tetramer contacts (Figure 1.2). The dimer contacts of each monomer reside
primarily in the N-terminal domain which contains the amidoligase domain where UTP is
phosphorylated by ATP. 60% of the residues involved in the dimer-dimer contact are
nonpolar and half of the buried nonpolar residues reside in a helix-loop-helix interdimer
contact loop (residues 93-130, E. coli numbering). The strong association through buried
nonpolar dimer-dimer contacts is one explanation of how CTPS can be found primarily as a
soluble dimer when inactive (Endrizzi et al., 2004).
In the apo structure of CTPS from E. coli, large “trenches” between the association of
two dimers (tetramer) were noted by the authors. The contact sites of two dimers and the
formation of the “trenches” corresponded to the amidoligase domain of CTPS. Comparing
the structure of the amidoligase domain of CTPS to that of the most structurally similar
protein (dethiobiotin synthetase) and the highest conservation of residues in this area contains
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three anion-binding sites (i.e. phosphate binding sites) allowed for the modeling in of the
ATP and UTP binding sites, which modeled to the “large” trenches between the two dimers.
The walls of the ATP and UTP binding sites were contributed by residues from three
of the subunits in the tetramer, providing evidence of how ATP and UTP can induce
tetramerization of CTPS (Figure 1.3). The authors use the appropriate analogy that ATP and
UTP are like “mortar” holding the tetramer of CTPS together (Endrizzi et al., 2004). One of
the crystal structures of T. thermophilus had three SO42- bound, which mimics the binding of
phosphates, and allows the modeling of ATP and UTP into the CTPS structure. Based upon
where the ATP and UTP were bound, required contacts from three of the four subunits
further supporting the idea that ATP and UTP act as a “mortar” for tetramer formation. The
residues identified for coordinating the phosphates were well conserved from a variety of
species providing further evidence that ATP and UTP do bind to the tetramer of CTPS in this
fashion (Goto et al., 2004). Also, the need for ATP and UTP binding for tetramer formation
could explain the cooperative binding observed for ATP and UTP in some of the earlier
biochemical studies.
1.1.6.2 CTP Binding Site
The CTP binding site in the E. coli apo CTPS was determined by identifying residues
in the CTPS structure that corresponded to residues in Chlamydia trachomatis and Chinese
hamster CTPS that when mutated were insensitive to CTPS inhibitors, had decreased CTP
inhibition and increased UTP amination activity (Whelan et al., 1993; Wylie et al., 1996).
Based upon the location of these residues, CTP bound to the CTPS tetramer in such a way
that the residues that interact with the phosphates of CTP also are the same residues that
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Figure 1.2 Model of Concentration Dependent Tetramerization of CTPS
Two dimers form a tetramer under high concentration of CTPS protein. Amidoligase
domain (ALase, N-terminus), glutamine amidotransferase (GATase, C-terminus) and flexible
linker connecting both domains are shown. Note how less compact the tetramer is compared
to the tetramer in Figure 1.3.
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Figure 1.3 Model of Ligand-induced CTPS Tetramer Formation
UTP and ATP bind to the tetramer interface solidifying the tetramer. GTP is thought
to bring the GAtase (glutamine amidotransferase domain) in closer contact with the ALase
(amidoligase domain). Note how more compact the tetramer is compared to the
concentration induced tetramer (Figure 1.2).
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interact with the phosphates of UTP, demonstrating how CTP could compete with UTP
binding and thus inhibit CTP synthesis (Endrizzi et al., 2004).
In support of this model a crystal structure of E. coli CTPS in complex with CTP
found that CTP bound as predicted previously. Furthermore, the CTP-CTPS co-crystal
structure demonstrated that multiple subunits of CTPS make contact with CTP, similar to
how UTP is thought to bind. The contact of CTP with multiple subunits may explain how
CTP, especially at lower concentrations of CTP, can enhance activity. The same analogy
describing ATP and UTP as “mortar” holding together the tetramer was used by the same
authors for how CTP can be promoting CTP synthesis under some conditions (e.g. low
concentration of CTP) by promoting tetramerization (Endrizzi et al., 2005).
1.1.6.3 GTP Binding Site
A possible GTP binding site in apo E. coli CTPS was identified by comparing the
glutamine amidotransferase domain of CTPS with that of other GTP binding proteins (EF-Tu
and EF-G). The proposed GTP binding site was found near a cleft adjacent to the supposed
entrance to the glutaminase site. The proposed GTP binding site contains a 3Å opening
which would allow solvent access to the glutaminase reaction site. The binding of GTP is
proposed by the authors to occlude this 3Å opening and block access of solvent molecules
such as exogenous ammonia to the glutamine amidotransferase region of CTPS. This GTP
binding site in CTPS is similar to the “lid” structure found in other glutamine
amidotransferases (e.g. CPS) sealing the glutaminase region of the enzyme from exposure to
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the solvent. It is also proposed that GTP binding may bring the catalytic residues required
for glutamine hydrolysis closer to the glutamine for optimal catalysis (Endrizzi et al., 2004).
Using data from mutational analysis and sequence conservation (Iyengar and Bearne,
2003; Simard et al., 2003; Willemoes, 2003) a GTP binding site was suggested in the crystal
structure from T. thermophilus (Goto et al., 2004). The GTP binding site corresponds to the
same “lid” region of the glutamine amidotransferase domain described in the E. coli
structure, but also includes residues from the amidoligase domain as well. The opportunities
for the glutamine amidotransferase domain and amidoligase domain to come in close enough
proximity to bind GTP is increased when both UTP and ATP are present suggesting that
GTP binding may act to stabilize the conformation where the glutamine amidotransferase
domain and the amidoligase domain are in close contact (Figure 1.3). Although the authors
fail to use the mortar analogy that was used to describe how ATP and UTP stabilize tetramer
formation, the same analogy could be used to describe how GTP holds the amidotransferase
domain and the amidoligase domain together thus increasing CTPS activity. The model of
GTP binding proposed, based on crystal structures from T. thermophilus and E. coli, is
supported by mutation of these residues predicted by the crystal structures to be involved in
GTP binding (Willemoes et al., 2005).
1.1.6.4 Glutamine Amidotransferase Domain
The glutamine amidotransferase (GATase) domain is found in other glutamine
hydrolyzing enzymes including carbamoyl phosphate synthetase (CPS), which is involved in
uridine biosynthesis. The GATase domain of CTPS contains many conserved residues found
in other GATases domains of the same family. The triad family of GATase domains, of
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which the CTPS GATase domain is a part of, is defined by the catalytic triad of cysteine-
histidine-glutamate. Superimposing the GATase domain of CTPS on CPS reveals that
Cys379, His515 and Glu517 (E. coli numbering) are the triad catalytic residues in E. coli
CTPS. In all triad family of glutaminases there exists an “oxyanion hole” for the
stabilization of the tetrahedral transition state of the glutaminase reaction (i.e. stabilizes the
sidechain carboxylate on glutamine). In the crystal structure of apo CTPS from E. coli this
“oxyanion hole” was proposed to be formed by the amides of the main peptide chain of
residues Gly352 and Leu380 (Endrizzi et al., 2004). The formation of the “oxyanion hole”
by these residues was confirmed in the T. thermophilus structure of glutamine-bound CTPS.
In addition to confirming the catalytic triad residues suggested in the E. coli apo crystal
structure, the glutamine-bound T. thermophilus crystal structure revealed that Tyr64, part of
the amidoligase domain, and His522 and Arg470 (T. thermophilus numbering) coordinate a
water molecule, which is proposed to be in favorable orientation for catalytic action (e.g.
hydrolysis of glutamine) (Goto et al., 2004). Interestingly, in the T. thermophilus glutamine-
bound crystal structure of CTPS a second His-Glu pair (His471 and Glu474, T. thermophilus
numbering) is found in close proximity to the catalytic cysteine and is suggested by the
authors to also be involved in catalysis. The distances between the histidine residues and the
catalytic cysteine in CTPS are larger than the distances found in other triad family of
GATases (including CPS) (Thoden et al., 1999) except for anthranilate synthase (Knochel et
al., 1999) suggesting that one possible mechanism by which GTP could increase glutaminase
activity would be by bringing the catalytic residues in closer proximity to the substrate (Goto
et al., 2004).
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Also observed in GATases of other family members is an ammonia tunnel where the
liberated ammonia exits the catalytic site and in the case of CTPS is passed to the
amidoligase domain to form CTP. In the apo structure of CTPS from E. coli a relatively
large solvent-filled “vestibule” was identified that connects the GATase domain to the
amidoligase domain via the ammonia tunnel. A conserved insert in CTPS and not found in
the GATase domain of CPS, amino acids 297-301 (E. coli numbering), contributes to the
wall of the vestibule and creates this opening by diverting sidechains that would normally
occlude this opening in CPS. The vestibule contains a number of hydrogen bonding groups
that could coordinate the liberated ammonia into the ammonia tunnel, which ultimately leads
to the amidoligase domain where the 4-phosphoryl UTP can be found. The vestibule is also
solvent accessible through the 3Å opening, where GTP is proposed to bind suggesting that
when GTP and glutamine are both bound ammonia cannot access the vestibule and this
limited access is thought to be the mechanism by which GTP inhibits CTPS activity when
exogenous ammonia is used as a substrate (Endrizzi et al., 2004). Connected to the vestibule
is a passage way that exits to the amidoligase active site in close proximity to where the 4-
phosphoryl UTP intermediate is thought to reside. There exists a restriction point between
the vestibule and the proposed exit composed of Pro54 and Val60 (E. coli numbering), which
the authors suggest is a gate which allows access of the ammonia from the
vestibule/ammonia channel to the amidoligase domain. Two conformations of His57 (E. coli
numbering) located in the amidoligase domain were noted by the investigators. One
conformation of His57 has its side chain next to where UTP is thought to bind and the other
conformation occludes the exit from the vestibule/ammonia tunnel suggesting that UTP
binding may alter the conformation of His57 such that ammonia is allowed to enter the
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amidoligase domain and react with the 4-phosphoryl UTP intermediate (Endrizzi et al.,
2004).
The structure of CTPS from T. thermophilus that has three sulfates and glutamine
bound contains a Tyr64 (T. thermophilus numbering) from the amidoligase domain that
interacts with the amide group of glutamine and is suggested by the authors to act as a door
whereby the nascent ammonia released from the active site can enter the ammonia tunnel.
The gating of this door is thought to be ATP and UTP dependent such that when ATP and
UTP are bound, ammonia is allowed into the ammonia tunnel (Goto et al., 2004). This is the
same residue (Tyr64) projected to be involved in orienting the water molecule for glutamine
hydrolysis, suggesting UTP and ATP binding may alter the orientation of Tyr64 to more
favor glutamine hydrolysis. Having UTP and ATP controlling a critical residue in the
glutaminase region of CTPS allows the coupling the glutaminase reaction with the binding of
substrates (ATP and UTP) needed for the next catalytic step in CTPS.
1.1.6.5 Amidoligase Domain
The amidoligase domain, which is located on the N-terminus of CTPS, binds UTP
and ATP and catalyzes the phosphorylation of UTP to the 4-phosphoryl UTP intermediate
followed by nucleophilic attack by ammonia on the four position of UTP to generate CTP.
Additionally, many of the contact sites for tetramer formation reside in the amidoligase
domain (Figure 1.3). The amidoligase domain most closely resembles that of dethiobiotin
synthetase (DTBS) and the folds of the kinase domain within the amidoligase domain most
closely resemble members of the ATP/GTPase superfamily such as APS kinase (Endrizzi et
al., 2004). The active site for the amidoligase domain resides between the binding site for
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the two homodimers and residues from multiple subunits contribute to ATP and UTP binding
(Figure 1.3). Unfortunately, thus far crystal structures with sulfates bound have been solved
and the binding sites for UTP and ATP are modeled into the CTPS structure based on the
location of ATP and UTP other structurally similar proteins as well as the location of the
sulfates, which does not allow for a rigorous interrogation of how the amidoligase domain
may function.
1.1.6.6 Reaction Mechanism and Conformational Change
Evidence from the crystal structures from apo, SO42- bound and glutamine bound
CTPS from T. thermophilus suggests a model whereby upon ATP and UTP binding the
glutamine amidotransferase domain and the amidoligase domains of CTPS come closer
together (Figure 1.3) allowing passage of the liberated ammonia from the glutaminase
reaction to the waiting 4-phosphoryl UTP in the amidoligase domain. In the structure of T.
thermophilus CTPS (apo, SO42- and glutamine bound) no ammonia tunnel was observed
between the glutamine amidotransferase domain and the amidoligase domain. The authors
support a model whereby ATP and UTP binding promote a conformational change involving
the rotation of the glutamine amidotransferase domain 25° towards the amidoligase domain
allowing a channel to form for ammonia propagation from the glutamine amidotransferase
domain to the amidoligase domain (Goto et al., 2004). There are several pieces of evidence
supporting and making this model plausible. One is that there is a flexible linker region
separating the amidoligase domain from the glutamine amidotransferase domain permitting
such movement. Another piece of evidence is that in the SO42--bound CTPS the glutamine
amidotransferase domain is slightly rotated towards the amidoligase domain demonstrating
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that there is flexibility in this direction. Further evidence supporting a conformational
change is that without ATP and UTP and at high protein concentration, the apparent
molecular weight as determined by dynamic light scattering was 470,000 and in the presence
of ATP and UTP the apparent molecular weight was the more expected value of 250,000,
suggesting that the ATP and UTP bound CTPS tetramer is more compact (Figure 1.3) than
the unbound CTPS (Figure 1.2). The authors also noted that the residues proposed to be
involved in this interaction between the two domains are disordered and/or highly mobile
suggesting these residues could be involved in conformational changes of CTPS (Goto et al.,
2004). As mentioned in the section regarding GTP binding, evidence from mutational
analysis and sequence conservation suggest that GTP binding involves residues from both the
glutamine amidotransferase domain and the amidoligase domain and upon the
conformational change proposed by the authors, these residues would be in closer proximity
to bind GTP (Goto et al., 2004). GTP binding would act as a stabilizing molecule promoting
the more compact tetramer formation (Figure 1.3) and/or the formation of the ammonia
tunnel, which may in part explain how GTP allosterically activates CTPS.
1.1.7 CTPS Regulation
1.1.7.1 Transcriptional Regulation
The only published transcriptional regulation of CTPS has been demonstrated in
bacteria. CTPS transcription is regulated in bacteria, at least in gram positive bacteria, by the
formation of a terminator hairpin structure in the mRNA leader sequence of CTPS under high
levels of CTP and formation of an antiterminator hairpin in the leader sequences when CTP
levels are low. The formation of the terminator hairpin and the antiterminator hairpin are
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mutually exclusive and their formation is directly regulated by the availability of CTP. In the
nascent mRNA leader sequence of bacteria CTPS there is the sequence 5’-gggc-3’, where the
polymerase will stutter (also known as reiterative transcription) if not enough CTP is
available for adding the last “c” in this sequence. Instead of adding a C, extra G residues will
be added until a C is finally added to continue with the transcription. The extra G’s added
will form the antiterminator hairpin structure at the exclusion of the formation of the
terminator hairpin allowing transcription of CTPS to proceed. However, if CTP is readily
available for the transcription of the last C in the 5’-gggc-3’ sequence, the terminator hairpin
structure will form and transcription of CTPS will be halted (Meng et al., 2004).
The transcription factor c-Myc has been shown to regulate other nucleotide metabolic
enzymes (Mai and Jalava, 1994; Miltenberger et al., 1995; Schuhmacher et al., 2001), we
therefore investigated CTPS protein expression in c-Myc -/- cells. CTPS protein, as assessed
by immunoblot, was lower in c-Myc-/- cells than in c-Myc+/+ cells. Re-addition of c-Myc (c-
Myc adenovirus) into c-Myc-/- cells increased CTPS expression (Figure 4.12). The increase
in CTPS1 expression in the c-Myc addback cells was further enhanced in the presence of
serum, indicating that growth factor mediated CTPS1 protein expression may require c-Myc.
Additionally, we have identified two canonical E-boxes (c-Myc binding sites), CACGTG,
(Blackwell et al., 1990) at -70 and -300 base pairs (bps) upstream from the translation start
site of human CTPS1. This evidence suggests that the transcription factor c-Myc may
coordinately regulate the expression of CTPS with other pyrimidine metabolic enzymes (e.g.
CAD) in mammalian cells (Eric M. Wauson and Matthew J. Higgins, unpublished
observations).
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1.1.7.2 Post-transcriptional Regulation
1.1.7.2.1 Translation Regulation
Translation regulation of CTPS has not been studied to date, but the mRNA for
human CTPS1 contains a ~150 bp 5’ UTR and an even larger ~900 bp 3’ UTR giving ample
sequence for regulatory proteins to bind and RNA secondary structures to form.
1.1.7.2.2 Regulation of CTPS by Phosphorylation
The study of CTPS phosphorylation has been studied extensively in the yeast S.
cerevisiae. PKC was the first kinase shown to phosphorylate URA7. Comparison of PKC
phosphorylation of URA7 in vitro with the phosphorylation of URA7 in vivo revealed that in
vitro PKC phosphorylates URA7 on both serines and threonines, whereas URA7 from intact
cells was found to be primarily phosphorylated on serine residues. Furthermore, separation
of tryptic peptides by 2D-TLC from in vitro PKC-phosphorylated URA7 and in vivo
phosphorylated URA7 revealed additional phosphorylated peptides from the in vitro
phosphorylated URA7 than the in vivo phosphorylated URA7, indicating that, in vitro, PKC
is phosphorylating sites not phosphorylated in vivo (Yang and Carman, 1995).
Phosphorylation of URA7 by PKC in vitro increased the apparent Vmax with respect to UTP
under subsaturating ATP concentrations and the phosphorylated enzyme had a greater
apparent affinity for ATP than the native enzyme. In vitro phosphorylation of URA7 by
PKC also reduced feedback inhibition by CTP under subsaturating concentrations of ATP.
PKC phosphorylation did not affect regulation of URA7 activity by glutamine and GTP,
indicating that in vitro phosphorylation of URA7 by PKC increases CTPS activity under
subsaturating conditions of ATP not by altering CTPS activity with respect to glutamine and
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GTP, but by altering substrate affinity and the affinity for CTP feedback inhibition (Yang et
al., 1996).
Possible PKC phosphorylation sites in URA7 were identified by using synthetic
peptides derived from sequences in URA7 containing amino acid residues; S36, S330, S354,
and S454 (S. cerevisiae numbering) (Park et al., 2003). However, when non-
phosphorylatable mutants of full length URA7 were incubated in vitro with PKC, only the
non-phosphorylatable, S330A, mutant had decreased phosphorylation suggesting this is the
major PKC site in intact cells (Park et al., 2003). CTPS activity of these phosphorylation site
mutants revealed that S36A and S354A had decreased CTPS activity, S330A caused an
increase in activity and S454A had no significant effect on activity (Park et al., 2003).
Interestingly, S330 is already an alanine in human CTPS1.
Additionally, this same group has identified in vitro S424 as a protein kinase A
(PKA) phosphorylation site (Park et al., 1999). The non-phosphorylatable S424A mutant
showed decreased CTPS activity and greater sensitivity to CTP feedback inhibition (Park et
al., 1999). As was observed with in vitro phosphorylation of URA7 with PKC, PKA also
stimulated URA7 activity (Yang and Carman, 1996). PKA stimulated URA 7 activity by
increasing the Vmax with respect to UTP, increasing both the Vmax and the affinity for ATP
and decreasing the ability of CTP to feedback inhibit URA7. As observed with PKC
phosphorylation of URA7, the effects of PKA on URA7 activity were more apparent at
subsaturating concentrations of ATP (Yang and Carman, 1996). Phosphorylation of S424 in
URA7 by PKC and PKA was also shown to regulate phosphatidylcholine biosynthesis via
the Kennedy pathway for phospholipid synthesis (Choi et al., 2003). Most recently
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expression of human CTPS1 in S. cerevisiae showed that PKA and PKC could phosphorylate
human CTPS1. Human CTPS1 was phosphorylated on Thr455 by both PKA and PKC
whereas Ser462 was only phosphorylated by PKC (Chang et al., 2007; Choi and Carman,
2007; Han et al., 2005). Mutation of Thr455 to alanine increased the amount of CTP and
increased CTPS activity in cells suggesting that phosphorylation of this residue decreases
CTPS activity (Chang et al., 2007; Choi and Carman, 2007; Han et al., 2005). Mutation of
S462 to alanine decreased CTPS activity suggesting that phosphorylation of S462 increases
CTPS activity (Chang et al., 2007).
1.1.8 CTPS Isoforms
Unlike in prokaryotes where only one isoform of CTPS is found, two or more CTPS
isoforms have been noted in studies involving eukaryotes. In humans two isoforms exist,
CTPS1 and CTPS2. CTPS1 has been mapped to chromosome 1 (1p34) and CTPS2 has been
mapped to chromosome X (Xp22). They share 74% sequence identity at the amino acid level
and 44-55% identity with the two isoforms found in S. cerevisiae, URA7 and URA8 (Huang
and Graves, 2003). Functional or expression differences between human CTPS1 and CTPS2
have not been investigated thus far. Since the sequence identity between human CTPS1 and
CTPS2 is high and the sequence identity of the region important for tetramer formation and
dimer formation is equally high (87% and 88%, respectively) it is likely that CTPS1 and
CTPS2 could form heterodimers and/or heterotetramers and this may explain some of the
complicated biochemical data that has been documented for CTPS in the last half century.
In S. cerevisiae both URA7 and URA8 can compensate for loss of one of the CTPS
enzymes, but the combined loss of URA7 and URA8 is lethal. Based on observations such
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as CTP concentration in null mutants, URA7 appears to be responsible for the majority of
CTP synthesized S. cerevisiae (McDonough et al., 1995; Ozier-Kalogeropoulos et al., 1994).
1.2 Pyrimidine Nucleotide Biosynthesis
1.2.1 Salvage Synthesis of CTP
The salvage synthesis of CTP requires the import of cytidine into the cell and
phosphorylation of cytidine to CTP (Figure 1.4). Nucleosides including cytidine are
imported into cells by membrane transporters. These transporters can be divided into two
groups; equilibrative nucleoside transporters (ENTs) and concentrative nucleoside
transporters (CNTs). The ENTs do not use an ion gradient to import nucleosides, but rely on
concentration gradients of nucleosides to drive transport. CNTs use an ion gradient, the
sodium ion gradient generated by the sodium-potassium-ATPase, for transporting
nucleosides. Cytidine is a substrate for both ENTs and CNTs. Of the ENTs, cytidine
transport is thought to be primarily through ENT2 since the apparent affinity of cytidine is
substantially higher for ENT2 than ENT1 (Ward et al., 2000).
Cytidine can also be imported by CNT1, CNT2 and CNT3. CNT1 is a pyrimidine
preferring CNT and has an apparent affinity in the low micromolar range for cytidine
(Pastor-Anglada et al., 2005). CNT3 has also been shown to transport cytidine with an
apparent affinity in the low micromolar range as well (Damaraju et al., 2005). CNT2 has
recently been shown to also transport cytidine (Nagai et al., 2006).
Once imported into the cell cytidine is “trapped” in the cell by being phosphorylated
to CMP by uridine/cytidine kinase (EC 2. 7. 1. 48, UCK) (Orengo, 1969). The next step in
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the salvage synthesis of CTP involves phosphorylating CMP to CDP by cytidylate kinase
(EC 2. 7. 4. 14, CMP kinase) (Ruffner and Anderson, 1969). The final step in the salvage
synthesis of CTP is catalyzed by nucleoside diphokinase ( EC 2. 7. 4. 6, NDPK, also known
as non-metastatic 23 (NM23)) (Berg and Joklik, 1954).
Because the cytidine levels in plasma from humans is around 0.7 µM (Traut, 1994),
the salvage pathway is thought to not play as significant of a role in the synthesis of CTP
compared to the de novo synthesis pathway of CTP.
1.2.2 De novo Synthesis of CTP
The rate-limiting reaction in the de novo synthesis of CTP is catalyzed by CTPS (EC
6. 3. 4. 2). The substrate, UTP, can be synthesized by either the salvage or de novo synthesis
pathway for UTP. The salvage pathway for UTP synthesis parallels the same steps as the
salvage pathway for CTP synthesis (Figure 1.4). The rate-limiting step in the de novo
synthesis pathway for UTP is catalyzed by the multifunctional CAD protein (EC 2. 7. 2. 9,
EC 2. 1. 3. 2 and EC 3. 5. 2. 3), which uses aspartate, bicarbonate, glutamine and ATP as
substrates and is allosterically activated by PRPP. The product of the CAD reaction is
converted to UMP through three more reactions, which is converted to UTP by the same
kinases that convert UMP to UTP from the salvage pathway (reviewed in (Jones, 1980)).
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Figure 1.4 Salvage and De novo Pyrimidine Biosynthesis Pathways
Pyrimidines can be synthesized either by the salvage pathway, which requires import
of nucleosides through the nucleoside transporters (ENTs or CNTs) and phosphorylation to
the appropriate nucleotide, or the de novo pathway, which involves CAD and CTPS as the
two rate-limiting enzymes for the synthesis of UTP and CTP, respectively. Also shown are
some of the CTP-requiring processes (e.g. protein sialylation, DNA/RNA synthesis,
phospholipid synthesis and N-linked glycosylation). PRPP is phosphoribosyl pyrophosphate.
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1.3 Chemical Inhibitors and CTPS in Disease
1.3.1 Involvement in Cancer
Not only are CTP and dCTP levels elevated in a variety of cancers, but CTPS activity
is also elevated in various cancers such as those derived from blood cells (leukemia), liver,
colon and lung (de Korte et al., 1987a; De Korte et al., 1986; de Korte et al., 1987b; de Korte
et al., 1985; Olah and Weber, 1979; Shewach, 1992; Sidi et al., 1985; van den Berg et al.,
1993; van den Berg et al., 1994; van den Berg et al., 1995; Verschuur et al., 1998; Weber et
al., 1980). Whether this increase in CTPS activity is due to elevated protein expression or
due to mutations in CTPS rendering the enzyme more active have not been thoroughly
investigated. Mutations rendering CTPS resistant to chemotherapeutic drugs as well as CTP
feedback inhibition have been documented, suggesting loss of CTP feedback inhibition may
be one mechanism by which CTPS activity is elevated (Blaney et al., 1993; Whelan et al.,
1993; Whelan et al., 1994; Wylie et al., 1996; Zhang et al., 1993).
1.3.2 Involvement in Parasitic, Bacterial and Viral Infection
Many pathogens exert control over metabolic processes that assure their replication
and survival. Since CTP levels are one of lowest concentration of NTPs in cells, control of
CTP synthesis is vital to survival of many pathogens. Viruses need to replicate their genome
for viral amplification and therefore require NTPs and/or dNTPs for pathogenesis. Several
CTPS inhibitors alone or in combination therapy have demonstrated potent antiviral
properties against viruses such as influenza, parainfluenza, coxsackie, sindbis, cytomegalo,
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HIV, poxvirus, hemorrhagic fever and yellow fever (Andrei and De Clercq, 1993; De Clercq
et al., 1991; Dereuddre-Bosquet et al., 2004; Gao et al., 2000; Neyts and De Clercq, 2003;
Neyts et al., 1996).
African sleeping sickness is caused by trypanosomes (protozoans), which are spread
to humans upon a bite by a tsetse fly. CTP pools in trypanosomes are low compared to other
eukaryotic cells and trypanosomes do not have the ability to synthesize CTP via the salvage
pathway using cytidine, but do encode their own CTPS (Hofer et al., 1998; Hofer et al.,
2001). Trypanosome CTPS has a higher Km for UTP than mammalian CTPS possibly
explaining why CTP levels are lower in trypanosomes than in eukaryotic cells. Using the
glutaminase inhibitor, acivicin, at a concentration below where CNS toxicity is observed, it
was shown in mice that CTPS inhibition could suppress trypanosome infection
demonstrating that targeting CTPS could be a new therapy for African sleeping sickness
(Fijolek et al., 2007).
Other parasites and bacteria known to encode their own CTPS include Plasmodium
falciparum (malaria), Giardia intestinalis and Chlamydia trachomatis (Hendriks et al., 1998;
Jimenez and O'Sullivan, 1994; Tipples and McClarty, 1995). It may be possible to target the
CTPS from these organisms as well as providing a new therapeutic strategy.
1.3.3 CTPS Inhibitors
1.3.3.1 The Rise and Fall of CPEC
As with many things throughout human civilization, good or bad, CPEC got its start
from fermentation. In 1979, a novel carbocyclic nucleoside was discovered in a Japanese
fermentation broth and named neplanocin A (Hayashi et al., 1980). Neplanocin A was quite
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toxic and became a lead compound for synthesis of other carbocyclic nucleosides.
Approximately 20 purine and pyrimidine analogs of neplanocin A were synthesized and
evaluated for antitumor and antiviral properties (Arita et al., 1983). Cyclopentenyl cytosine,
CPEC, was the most biologically active pyrimidine compound tested. CPEC was shown to
be effective against a variety of tumor cells and tumor xenografts including colon carcinoma
cells, leukemia cells, human lung cancer, melanoma and breast cancer cells (Glazer et al.,
1986; Glazer et al., 1985; Marquez et al., 1988; Moyer et al., 1986). In 1989, the active
metabolite of CPEC, CPEC triphosphate, was identified and CTPS was found to be the target
(Kang et al., 1989). The pharmacokinetics of CPEC were studied thoroughly in nonhuman
primates, dogs and rodents. In both rodents and dogs CPEC was primarily eliminated by
renal excretion, but in nonhuman primates the primary route of elimination was by
deaminating CPEC to cyclopentenyl uracil, CPEU (Blaney et al., 1990; Zaharko et al., 1991).
Since CPEU inhibits uridine/cytidine kinase, UCK, it was thought that the antitumor effect of
CPEC may be due to inhibition of UCK. However, testing revealed that not only is CPEU
not as cytotoxic as CPEC, but pretreatment of cells with CPEU protected cells from the
cytotoxic effects of CPEC (Blaney et al., 1992). Since there seemed to be an active cytidine
deaminase converting CPEC to CPEU in primates, it was concluded that a continuous
infusion of CPEC would be need for clinical trials. Phase I clinical trials commenced in
1994 with the continuous infusion of CPEC resulting in plasma levels of 0.4 to 3.1 µM
CPEC, but the promise of CPEC as a new antitumor drug was thwarted when two people
died of hypotension in the study (Politi et al., 1995). The exact reason for how or if CPEC
caused hypotension is currently unknown. Perhaps if we understand more of how CTPS
functions we can develop new therapies targeting CTPS without the devastating side-effects.
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Although, CPEC is not currently being used clinically it is still a useful tool for studying the
role of CTPS in in vitro cell systems.
1.3.3.2 Glutaminase Inhibitors
Glutaminase inhibitors such as acivicin and DON target the glutaminase reaction of
CTPS. Although, many other glutaminase containing enzymes have the acivicin and DON
targeted catalytic residues (catalytic cysteine of the catalytic triad), much of the
antiproliferative effects of acivicin and DON are attributed to inhibition of CTPS as
suggested by observations in leukemia cells (Fischer et al., 1988; Lyons et al., 1990). GMP
synthase is the other glutaminase containing enzyme that acivicin inhibits almost as well as
CTPS (Aoki et al., 1982; Weber et al., 1984). Acivicin works by alkylating the catalytic
cysteine rendering the glutaminase nonfunctional (Cooney et al., 1976; Hanka and Dietz,
1973). It is possible the reason acivicin targets the glutaminase domain of CTPS better than
other glutaminases is because the catalytic pocket is larger in CTPS than other glutaminases.
Although, DON will also covalently inhibit the glutaminase reaction of CTPS, acivicin has a
longer half life in vivo and penetrates the blood brain barrier better making it a better
therapeutic drug in many instances (Chikhale et al., 1995; McGovren et al., 1982; Sullivan et
al., 1988).
Another glutaminase inhibitor is glutamate -semialdehyde, GSA, which mimics the
transition state of the glutaminase reaction and reversibly inhibits glutaminase activity
(Bearne et al., 2001; Bearne and Wolfenden, 1995). GSA was shown to be a potent
reversible inhibitor of CTPS (Bearne et al., 2001). Unfortunately, GSA exists in unfavorable
equilibrium with pyrroline-5-carboxylate (P5C) a cyclic molecule, which does not have anti-
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glutaminase activity. Interestingly, P5C is an intermediate in proline, glutamate and
ornithine metabolism (review see (Jones, 1983; Jones, 1985)) suggesting that under
conditions where these intermediates accumulate and/or are released, GSA could form and
inhibit CTPS.
1.3.3.3 Other CTPS Inhibitors
3-deazauridine (DAU), when phosphorylated to the triphosphate form, competes with
UTP for binding to CTPS and thereby inhibiting CTP biosynthesis (McPartland et al., 1974;
Van Kuilenburg et al., 1994). Additionally, DAU in combination with cytosine arabinoside
(AraC) was shown to have synergistic effects in leukemia cells (Momparler et al., 1991).
1.4 CTP Dependent/Requiring Processes
1.4.1 DNA/RNA Biosynthesis
dCTP and CTP are essential for synthesis of DNA and RNA, respectively. Whether
pools of nucleotides exist for the formation of DNA/RNA or other nucleotide conjugated
products has been suggested. For instance, using rat hepatocytes labeled with [3H]uridine
[3H]cytidine and/or [14C]orotic acid (intermediate in the UTP de novo synthesis pathway) it
was suggested that salvage synthesized cytidine nucleotides were more preferentially used
for RNA synthesis and synthesis of cytidine compounds (Pels Rijcken et al., 1993). Another
study using a similar strategy of labeling cells with radiolabeled precursors found in
undifferentiated PC12 cells that the salvage pathway of CTP synthesis seemed to be more
preferred for RNA synthesis (Slingerland et al., 1995). Investigation of the pools of dCTP
involved in DNA repair has found that the import of deoxycytidine is preferentially used for
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the DNA repair in response to alkylating DNA damaging agents and radiation, whereas
intracellular stores of dCTP are probably preferentially used for replicative DNA synthesis
(Xu et al., 1995). Based on multiple studies, some of which are mentioned above, it seems
that there is a compartmentation of nucleotides involved in DNA/RNA synthesis, and
possibly other nucleotide requiring process, but evidence directly demonstrating such pools
exist is lacking.
1.4.2 CTP Involvement in Thymidine Metabolism
Interestingly, an unexpected link between CTP metabolism and dTTP formation
involving CTPS has been elucidated. CHO cells selected for resistance to AraC required
exogenous thymidine, deoxycytidine or deoxyuridine for survival and levels of dCTP were
found to be elevated (Mark Meuth, 1979). Further investigation revealed elevated CTP and
dCDP levels, but uridine nucleotide levels remained unchanged suggesting that cytidine
nucleotides are involved in thymidine auxotrophy. Additionally, CTP was demonstrated to
inhibit reduction of UDP to dUDP, which through several reactions is converted to dTTP (de
Saint Vincent et al., 1980). It was later shown in thymidine auxotrophic cell lines that CTPS
was less sensitive to CTP feedback inhibition than the revertant cells and this was most likely
the cause for the elevated CTP levels and the AraC resistance originally observed (Trudel et
al., 1984). The model proposed for how increased CTP levels can cause thymidine
auxotrophy is that increased CTP levels leads to increased CDP, which, along with UDP, is a
substrate for ribonucleotide reductase and since ribonucleotide reductase has a higher affinity
for CDP than UDP, UDP is not reduced to dUDP to form dTTP resulting in thymidine
auxotrophy (Figure 1.4) (Eriksson et al., 1979; Trudel et al., 1984). Analysis of DNA from
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CTPS resistant to various drugs including AraC revealed a clustering of mutations proposed
and confirmed later by structural studies to be in the CTP binding pocket (Whelan et al.,
1993). The ability of CTP levels to impact dTTP formation demonstrates a possible role for
CTP in regulating the balance of dNTPs needed for DNA synthesis.
1.4.3 Phospholipid Biosynthesis
Phospholipids are not only structural molecules forming membranes around cellular
structures, but are also involved in signaling through the formation of docking sites for
proteins and generating second messengers. CTP is required for phospholipid synthesis
because it is used to form the energy rich intermediates involved in phospholipid synthesis.
Elevated CTP levels can increase the flux through the rate-limiting enzyme involved in
phosphatidylcholine biosynthesis most likely resulting in increased phosphatidylcholine
biosynthesis (Choy et al., 1980). Most phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) are synthesized via the Kennedy pathway, where
phosphocholine and phosphoethanolamine react with CTP to form CDP-choline and CDP-
ethanolamine. CDP-choline and CDP-ethanolamine then react with diacylglycerol to form
PC and PE, respectively (Figure 1.5) (Kennedy, 1956a; Kennedy, 1956b; Kennedy and
Weiss, 1956). Phosphatidylinositol (PI) and cardiolipin also require CTP for synthesis as
they are synthesized from the intermediate CDP-diacylglycerol (CDP-DAG) (Figure 1.5)
(Benjamins and Agranoff, 1969; Hostetler et al., 1971; Paulus and Kennedy, 1960; Prottey
and Hawthorne, 1967). In mammals phosphatidylserine (PS) is synthesized by a base
exchange reaction of serine with either PC or PE, whereas in yeast PS is synthesized from
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CDP-DAG and serine (Figure 1.5) (Borkenhagen et al., 1961; Kuge et al., 1986a; Kuge et al.,
1986b).
Inhibition of CTPS with CPEC decreased PC, PE, PI, PS and cardiolipin levels in
H9c2 cardiac myoblasts (Hatch and McClarty, 1996). Interestingly, neutral lipids were
slightly increased in the presence of CPEC suggesting inhibition of phospholipid synthesis
results in increases in neutral lipid formation.
1.4.4 Protein Sialylation
Sialic acids are comprised of over 50 related sugars derived from neuraminic acid (5-
amino-3,5-dideoxy-D-glycero-D-galacto-2-nonulopyranos-1-onic acid) or
deaminoneuraminic acid (KDN, 3-deoxy-D-glycero-D-galacto-2-nonulopyranos-1-onic
acid). The sialylation proteins is important in a variety biological processes, such as cell-cell
communication (for review (Crocker et al., 2007; Munday et al., 1999; Varki, 2007). Sialic
acids are activated before they are transferred to proteins by reacting with CTP to form CMP-
sialic acid. Incubation of cells with the CTPS inhibitor, DAU, can inhibit the regeneration of
surface sialic acid containing proteins demonstrating that CTP levels can influence plasma
membrane expression of sialylated proteins (Hindenburg et al., 1985).
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Figure 1.5 dTTP Biosynthesis Pathway
Both UDP and CDP are substrates for ribonucleotide reductase (RR), but CDP has a
two fold higher affinity for RR. Under elevated CTP and CDP conditions CDP is more
readily reduced at the expense of reducing UDP and thought to cause decreased levels of
dTTP.
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Figure 1.6 Phospholipid Synthesis Pathway
Biosynthesis of phospholipids requires CTP. Shown is the Kennedy pathway for the
synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE). PC and PE can
also be synthesized from phosphatidylserine (PS). In addition to being required for the
Kennedy pathway, CTP is required for the formation of CDP-diacylglycerol (CDP-DAG)
from phosphatidic acid (PA). CDP-DAG is used in the synthesis of cardiolipin (CL),
phosphatidylinositol (PI) and PS.
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1.4.5 N-linked Glycosylation
Attachment of oligosaccharides to asparagine residues of proteins requires that these
oligosaccharides are assembled on dolichyl (dolichol) phosphate, which is formed by
dolichol kinase using CTP and not ATP or GTP as the phosphoryl donor for the
phosphorylation (Burton et al., 1979). Thus, this is another CTP-dependent process. The
primary means of regulating the involvement of dolichol in N-linked glycosylation is by
phosphorylation suggesting CTP may play an important role in regulating N-linked
glycosylation (for review see (Rip et al., 1985)).
1.5 Role of GSK3 in Metabolism Regulation
GSK3 was originally identified as the third kinase responsible for the
phosphorylation of glycogen synthase, which decreased glycogen synthase activity (Embi et
al., 1980; Rylatt et al., 1980). Since this seminal discovery, multiple substrates and cellular
roles of GSK3 have been elucidated. Many GSK3 substrates identified are involved in
metabolism (e.g. glycogen synthase, acetyl CoA carboxylase, insulin receptor substrate,
pyruvate dehydrogenase) demonstrating a prominent role for GSK3 in regulating metabolism
(reviewed in (Frame and Cohen, 2001)). Interestingly, the carboxy-terminus of mammalian
CTP: phosphocholine cytidylyl transferase (CCT, EC: 2.7.7.15), which is the rate-limiting
enzyme in phosphatidylcholine biosynthesis and the next biosynthetic step in phospholipid
metabolism, is phosphorylated on multiple sites (MacDonald and Kent, 1994; Watkins and
Kent, 1991). Moreover CCT activity is decreased by phosphorylation (MacDonald and Kent,
1994; Watkins and Kent, 1991). Multiple phosphorylation sites in the carboxy-terminus of
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CCT are GSK3 consensus sites suggesting that phosphatidylcholine, and possibly
phospholipid synthesis in general, may be regulated by GSK3 phosphorylation of rate-
limiting enzymes, such as CCT and possibly CTPS1.
1.6 Specific Aims
Maintaining proper metabolic control of key metabolic pathways is critical to
sustaining homeostasis. Misregulation, either through genetic mutation or infection by a
pathogens, of key regulatory enzymes can contribute to diseases such as cancer. CTP is an
important nucleotide involved in processes including protein sialylation, phospholipid
synthesis, DNA/RNA synthesis and N-linked glycosylation. CTP concentrations in
mammalian cells are tightly controlled primarily by the enzyme CTPS. CTPS can bind four
nucleotides and glutamine making CTPS sensitive to and exquisitely regulated by
metabolites. In S. cerevisiae, URA7 activity was shown to be regulated by PKA and PKC
phosphorylation. Furthermore, phosphorylation of URA7 was shown to impact phospholipid
synthesis.
The goal of this dissertation was to determine how mammalian CTPS1 was regulated
by phosphorylation and to determine CTPS1 interacting proteins, which may aid in further
determining how mammalian CTPS1 is regulated. For both of these aims, a human/rodent
specific CTPS1 antibody was developed. Using hCTPS1 from [32P]-orthophosphate labeled
HEK 293 cells that were treated with activators and inhibitors of interest. Since URA 7 was
phosphorylated by PKA and PKC, the ability of hCTPS1 to be phosphorylated by PKA
and/or PKC was first investigated (specific aim 1). Determination of phosphorylation sites in
endogenous hCTPS1 was done by mass spectroscopy and verified using phospho-null
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mutants of the identified phosphorylation sites expressed in intact HEK 293 cells (specific
aim 2). Since many of the phosphorylation sites identified in yeast were not conserved in
human CTPS1, stimuli that regulated hCTPS1 phosphorylation was also investigated by
immunoprecipitating hCTPS1 from [32P]-orthophosphate labeled HEK 293 cells treated with
various factors (specific aim 3).
In addition to determining how hCTPS1 is regulated by phosphorylation, hCTPS1
interacting proteins were identified by mass spectrometry and one was verified by
immunoprecipitation and reciprocal immunoprecipitation (specific aim 4). Thus, these
studies provide a comprehensive analysis of the factors that regulate CTPS activity in
mammalian cells.
Specific Aims:
(1) Determine if PKA and/or PKC phosphorylate endogenous hCTPS1 (Chapter 3)
(2) Determine on what residues hCTPS1 is phosphorylated (Chapter 3)
(3) Determine what stimuli and/or kinases other than PKA and PKC phosphorylate
CTPS1 (Chapter 3)
(4) Determine hCTPS1 interacting proteins (Chapter 4)
CHAPTER
2. Experimental Procedures
2.1 Materials
Taxol and anti--tubulin antibody was purchased from Sigma. CPEC was acquired
from NCI (National Cancer Institute). GST-xPin1 was a kind gift from Dr. Anthony Means
(Duke Univesity). c-Myc-/- MEFs, c-myc+/+ MEFs and c-myc adenovirus were kind gifts
from Dr. Phil Nevins (Duke University).
2.2 CTPS Activity Assay
CTPS1 was immunoprecipitated as described above. Immunoprecipitates were
washed three times with 0.5 ml RIPA buffer without SDS containing 5 µg/ml leupeptin and a
final wash was done with 1 ml of 1 X CTPS reaction buffer (50 mM Tricine, pH8.1, 20 mM
MgCl2 and 5 mM KCl ). The volume was adjusted to 40 µl with 10 µl 5X reaction buffer
and 30 µl ddH2O. CTPS1 and 5X substrate mix (5 mM ATP, 0.5 mM UTP, 5 mM GTP,
100mM L-glutamine and 0.625 µCi/ml [14C]-UTP or 0.1 µCi/ml [3H]-UTP) were
equilibrated to 37ºC. The reaction was initiated by adding 10 µl of 5X substrate mix to 40 µl
of CTPS1 in reaction buffer and stopped after 45 minutes by adding 10 µl 200 mM EDTA
and removing tube to ice. CTPS1 reactions were reduced to dryness using a SpeedVac.
Dried supernatant pellets were resuspended in 10 µl of ddH2O. 3-4 µl of resuspended pellets
and 1 µl of 100 mM UTP/CTP/UDP/CDP standards were spotted onto polyethylimine (PEI)
cellulose plastic backed plates (Fisher Scientific) that were pre-washed 10 minutes with
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ddH20, 5 minutes with 0.65 N HCl and 1 minute with methanol. Nucleotides were resolved
using 0.65 N HCl as the ascending chromatography buffer. Areas corresponding to UTP,
CTP, UDP and CDP were visualized with a short wavelength UV light and nucleotide areas
containing radioactivity were visualized by exposing TLC plate to phosphorimage screen
overnight. Areas corresponding to UTP, CTP, UDP and CDP were excised and counted
using Ecoscint™ (Fisher Scientific) scintillation fluid.
2.3 Transfection of HEK 293 cells
75% confluent 100 mm plate were transfected with 5.6 µg DNA using
Lipofectamine™ as outlined by manufacturer. Briefly, 5.6 µg DNA and 22.5 µl
Lipofectamine™ were diluted with 560 µl DMEM. Diluted DNA and Lipofectamine™
solutions will be combined and allowed to incubate at room temperature for 30 minutes.
Following 30 minutes, 3.8 ml DMEM was added to each DNA/Lipofectamine™ solution and
the newly diluted DNA/Lipofectamine™ solution is added to a plate containing HEK 293
cells. After plate has incubated for 5 hours at 37ºC/5% CO2, FBS/penicillin/streptomycin in
DMEM is added to achieve a final concentration of 10% FBS/ 100 U/mL penicillin / 100
µg/mL streptomycin.
2.4 Transfection of HELA cells
1X106 HELA cells in a 100 mm plate was transfected with 7 µg DNA using
Lipofectamine™. 7 µg DNA and 60 µl Lipofectamine™ was diluted with 800 µl
Optimem™. DNA and Lipofectamine™ solutions will be combined and allowed to incubate
at room temperature for 30 minutes. DNA/ Lipofectamine™ solution will be diluted with 6.4
ml Optimem™ and layered onto HELA cells. Following incubation of HELA cells for 5
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hours at 37ºC/5% CO2, transfection media will be removed and HELA cells will be washed
with DMEM/10% FBS / 100 U/mL penicillin / 100 µg/mL streptomycin and placed in fresh
DMEM/10% FBS 100U/mL penicillin /100 ug/mL streptomycin.
2.5 Immunostaining
Cells were plated onto glass coverslips. Following treatment and/or
transfection glass coverslips were removed and fixed in 4% p-formaldehyde/4% sucrose in
phosphate buffered saline (PBS) for 10 minutes. Fixing reaction was quenched with 10 mM
glycine / 1% Triton X-100 in PBS. After washing coverslips three times with PBS with 1%
Triton X-100 (PBST), coverslips were placed in blocking solution consisting of 5% BSA/ 5%
horse serum in PBST for at least four hours. Blocking solution was removed and ~35 µl of
the primary antibody diluted in blocking solution will be added to each coverslip. Coverslips
were incubated in a humidifying chambers for 4 hours at room temperature to overnight at
4ºC. Following incubation with primary antibodies, coverslips were washed with PBST.
Secondary antibodies containing either Alexa 488™ or Alexa 594™ fluorophore was added
to coverslips and incubated at room temperature in the dark for 1 hour. Coverslips were
removed and washed 3 times with PBST. Washed coverslips were mounted onto glass slides
with Permafluor™ and sealed with finger nail polish.
2.6 Antibodies and immunoblotting.
Anti-CTPS1 (human) antibody was generated by Rockland Immunochemicals using a
C-terminal peptide (amino acids 578-591, H2N-CSEITELKFPSINHD-COOH) containing an
N-terminal cysteine for coupling to peptide affinity column and keyhole limpet hemocyanin.
Anti-CTPS1 antibody was purified from rabbit serum in a three step process. First, serum
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proteins including immunoglobulins were precipitated at 4ºC by adding ice-cold saturated
(NH4)2SO4 to a final percentage of 50%. (NH4)2SO4 precipitated proteins were resuspended
in a volume of PBS equal to the initial volume of serum and dialyzed overnight at 4ºC
against PBS. Second, 2.5 ml of (NH4)2SO4 purified serum protein solution was rotated with
0.5 ml (bead volume) protein A that has been equilibrated with 100 mM Tris pH 8.0. After
washing the protein A column with 100 mM Tris pH 8.0 and 10 mM Tris pH 8.0, bound
antibodies were eluted with 5 ml of 50 mM glycine pH 3.0. One ml fractions were collected
in microfuge tubes containing 100 µl 1 M Tris pH 8.0 to immediately neutralize pH. All
fractions were pooled and dialyzed overnight at 4ºC against PBS. Lastly, antibodies specific
for CTPS1 were separated from non-specific antibodies using a peptide affinity column
created with the antigenic peptide (H2N-CSEITELKFPSINHD-COOH ) and a Sulfolink
column (Pierce Biotechnologies) per manufacturers instructions. Eluted anti-CTPS1
antibodies were concentrated to about 350 µl and buffer exchanged to PBS with 0.05% NaN3
using 4 ml 10 kDa MWCO spin concentrators. Twenty µl aliquots were stored at -20ºC for
future use.
Immunoblotting for GSK3 (Santa Cruz) and phospho-GSK3 (Cell Signaling)
(/, Ser21/Ser9) was done by lysing HEK 293 cells with RIPA without SDS and
determining the protein concentration in lysate using the method of Bradford (Bradford,
1976). Lysates were prepared for SDS PAGE by adding an equal volume of 2X SDS sample
buffer (0.5 M Tris pH 6.8, 4% SDS, 20% glycerol, 10% -mercaptoethanol, 0.002 g/ml
bromophenol blue). 10 to 40 µg of protein was separated on an 8 or 10% discontinuous
buffer gel and proteins were transferred to polyvinylidene fluoride (PVDF) membrane
(Immobilin-P, Millipore). Membranes were blocked for one hour at room temperature or
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overnight in cold room with 3% w/v cold fish gelatin (Sigma) diluted with TBST (10 mM
Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20). Primary antibodies (1:1000 -phospho
(Ser9) GSK3 (Cell Signaling) and 1:1000 -GSK3 (Cell Signaling)) were diluted in 1%
w/v gelatin in TBST and incubated with membranes for 1 hour at room temperature (-
GSK3) or overnight at 4°C (-phospho (Ser9) GSK3, Cell Signaling). Membranes were
then washed with TBST three times five minutes each wash and incubated for one hour with
1:2000 goat anti rabbit (Santa Cruz) conjugated to horseradish peroxidase (for -GSK3) or
alkaline phosphatase (for -phopho (Ser9) GSK3). Membranes were washed three times
five minutes each wash with TBST and either visualized using enhanced chemiluminescent
kit (Amersham) per manufacturers instructions and exposing membrane to X-ray film or
using BCIP/NBT kit (Promega) to visualize alkaline phosphatase conjugated secondary
antibody as suggested by manufacturer.
2.7 Preparation of Peptides from Excised Bands for Mass Spectrometry
Protein bands excised from Coomassie blue stained gels will be cut into small
pieces and destained with 50 mM ammonium bicarbonate/ 50% acetonitrile solution. After
gel pieces have been destained they was dried down using a SpeedVac. Gel pieces will be
reswelled with 0.2 µg of trypsin and incubated overnight at room temperature. Supernatent
was removed to a new tube and peptides were further extracted with 60% acetonitrile/5%
formic acid. Volume of collected peptides were reduced to 10-15 µl using the SpeedVac.
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2.8 Phosphorylation site identification by mass spectrometry.
HEK 293 cells were labeled and immunecomplexes were separated as described
above. After separation of eluted proteins by SDS-PAGE, proteins were transferred to
nitrocellulose (Osmonics (GE Healthcare)). Proteins were visualized using MemCode
(Pierce Biotechnologies) per manufacturer instructions. Bands corresponding to CTPS1
were excised and cut into about 1 mm pieces. Membrane pieces were placed in a siliconized
microfuge tube and MemCode destaining was done as recommended by manufacturer. After
washing membrane pieces with ddH2O three times they were incubated with 1% w/v
polyvinylpyrolidone (PVP) suspended in 100 mM acetic acid for at least one hour at 37ºC.
Membrane pieces were washed four times with ddH2O to ensure residual PVP was removed.
Membrane pieces were incubated with 0.5 µg TPCK modified sequencing grade trypsin
(Promega) in 25 mM ammonium bicarbonate pH 8.0 overnight at 37ºC. Peptides were
collected by removing trypsin solution to a clean tube and the membrane pieces three times
were washed with ddH2O and removing each ddH2O wash to the same clean tube containing
the trypsin solution. The volume of collected peptides was reduced to a final volume of
about 10 µl using a speed vac. Recovery of radioactivity from membrane pieces was at least
85% as determined by Cerenkov counting. For separation of peptides on cellulose TLC
plate, peptides were washed at least three times with ddH2O to remove ammonium
bicarbonate. After the final ddH2O wash, peptides were resuspended in the first dimension
buffer (pH 1.9 buffer, 15 % v/v acetic acid and 5% v/v of 88% formic acid) to give a final
volume of about 8 µl. The peptides were spotted in a corner of a 10x10 cm cellulose TLC
plate, 1.5 cm from the sides of the plate. Peptides were electrophoresed using a Hunter thin
layer electrophoresis box at 1000 V for 32 minutes. After thoroughly drying the TLC plate,
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peptides were separated in the second dimension using Scheidtmann buffer (isobutyric acid-
pyridine-acetic acid-butanol-water, 65 : 5 : 3: 2: 29) (Scheidtmann et al., 1982). After
exposure of TLC plates to X-ray film or phosphorimager plate radioactive spots indicative of
phosphopeptides were eluted as described previously (Raska et al., 2002). Volume of
peptides was decreased to about 10 µl using a speed vac. Peptides were subjected to
nanospray electrospray ionization mass spectrometry (ESI-MS) on an Applied Biosystems
QSTAR® pulsar mass spectrometer in positive ion mode. Peptides were sequenced by ESI-
MS/MS using BioAnalyst software.
2.9 Cell Cycle Synchronization of HELA Cells
HELA cells were synchronized as described in (Erkmann et al., 2005).
2.10 In vivo labeling with [32P]orthophosphate.
100 mm tissue culture plates (Sarstedt Inc.) were coated with 0.02 mg/ml poly-D-
lysine (Sigma Aldrich) and washed with ddH2O. 7.5 X 106 HEK 293 cells were plated on
PDL coated plates. Cells were washed one time with 5 ml phosphate-free DMEM
(phosphate/pyruvate free DMEM (Invitrogen Inc.) supplemented with sodium pyruvate
(Invitrogen Inc.) giving a final concentration of 110 mg/L sodium pyruvate and the same
concentration of penicillin/streptomycin as described earlier). Three milliliters of phosphate-
free DMEM containing 10% dialyzed FBS (Invitrogen Inc.) was added to plates 30 minutes
prior to adding 1 mCi of [32P]-orthophosphate per plate (0.33 mCi/ml, MP Biomedical). In a
typical experiment, cells were labeled for 4 hours prior to manipulation. Labeling was
stopped by washing plates twice with 5 ml ice-cold PBS. Cells were lysed by scraping plates
in the presence of 0.5 ml of no SDS RIPA buffer. Immunoprecipitations were done as
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described above. Immunecomplex proteins were eluted from beads by boiling for 3 minutes
with Laemmli buffer. SDS-PAGE/autoradiography was done on eluted proteins.
2.11 Calf Intestinal phosphatase treatment of CTPS1
Immunoprecipitated CTPS1 (prepared as described earlier) was washed three times
with one milliliter RIPA buffer without SDS and one time with one milliliter 1X CTPS
reaction buffer. 10 µl 5X CTPS reaction buffer and 25 µl ddH2O was added to
immunoprecipitates and tubes were placed at 30°C for phosphatase reaction.
Dephosphorylation was initiated by adding 15 µl (1 unit/µl) calf intestinal phosphatase (CIP,
Roch Biochemicals) or 15 µl 50% glycerol (control reaction) to tubes containing
immunoprecipitated CTPS1 (50 µl total volume). Reactions were stopped by adding one
milliliter ice-cold 1X CTPS reaction buffer to dilute reaction components and placing tubes
on ice. Immunoprecipitates were washed again with ice-cold 1X CTPS reaction buffer.
2.12 GSK3 RNA interference.
3.5 X 105 HEK 293 cells were plated onto 60 mm poly-D-lysine coated plates and
incubated overnight. DMEM containing 10% FBS and penicillin/streptomycin (DMEM +
10% FBS + pen./strep.) was removed from cells and media was replaced with DMEM
containing 10% FBS and no antibiotics (DMEM + 10% FBS). RNA duplexes (Dharmacon)
were suspended as suggested by manufacturer and 15 µl of 20 µM RNA duplex was added to
one tube containing 285 µl DMEM + 10% FBS and mixed thoroughly. 12 µl of Dharmafect
1 was added to a second tube containing 288 µl DMEM + 10% FBS and mixed thoroughly.
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Tubes containing RNA duplexes and Dharmafect 1 were combined, mixed thoroughly and
allowed to stand at room temperature at 20 minutes. 2400 µl of DMEM + 10% FBS was
added to the duplex/Dharmafect 1 mixture to give a total volume of 3000 µl and the entire
mixture (3000 µl) was added to plates that had their media removed. Media was switched
the following day to DMEM + 10% FBS + pen./strep. Cellular manipulations were done the
following day after incubating cells overnight.
2.13 Pin1 RNA interference
Silencing of Pin1 was done as described for the silencing of GSK3
(Experimental Procedures).
2.14 In vitro GSK3 kinase reaction.
Endogenous CTPS1 or FLAG-CTPS1 was immunoprecipitated as described
above. Immunoprecipitates were washed one time with one milliliter 1X GSK3 reaction
buffer (20 mM Tris pH 7.5 at 25°C and 10 mM MgCl2) without DTT and 25 µl complete
GSK3 reaction buffer (20 mM Tris pH 7.5 at 25°C, 10 mM MgCl2, 10 µM ATP, 2 µl [32P]--
ATP (10 mCi/ml, PerkinElmer), 5 µg/ml leupeptin, 10 nM microcystin and 5 mM DTT) was
added to each immunoprecipitate. To each reaction 0.01 units of GSK3 purified enzyme
(New England Biolabs) was added and incubated at 30°C for 30 minutes with flicking tubes
occasionally to resuspend immunoprecipitates. Reactions were stopped by removing
supernatant, placing tubes on ice and adding 30 µl of 1X SDS sample buffer (See
immunoblotting for composition of SDS sample buffer) to immunoprecipitates.
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2.15 Plasmid construction and site-directed mutagenesis.
Full length cDNA containing human CTPS1 was purchased from Invitrogen Inc.
(IMAGE clone ID: 3355881). A C-terminal FLAG sequence was introduced after insertion
of human CTPS1 into pCDNA 4 myc/his using the compatible cohesive ends Eag1&Not1
and Xho1. Briefly, the CTPS1 IMAGE clone was digested with Eag1 and Xho1 and ligated
into pCDNA4 digested with Not1 and Xho1. Introduction of the C-terminal FLAG sequence
was done by first amplifying a C-terminal section of CTPS1 with the sense primer 5’-
CACGAAGCTTGGCAGAAGC-3’ (HindIII site is underlined) and antisense primer 5’-
GACTCGAGCGCTTGTCGTCATCGTCTTTGTAA TCCGCGTCATGATTTATTGATGG-
3’ (Xho1 site is underlined, FLAG sequence (DYKDDDDK) is boldface and mutation of
stop codon to alanine is italicized & underlined) and finally ligating the C-terminal amplified
section back into the pCDNA4 CTPS1 using HindIII and Xho1 restriction sites. A Kozak
sequence (GCCACC) was added upstream of the start codon (ATG) by amplifying an N-
terminal fragment of CTPS1 with the sense primer 5’-
CGCGGCCGCGCCACCATGAAGTACATTCTG-3’ (Not1 site is underlined and start
codon is boldface) and antisense primer 5’-CGGATCCGCGTCATGATTTATTGATGG-3’,
digesting the amplified N-terminal fragment with Not1 and Eco N1 and ligating the digested
N-terminal fragment into pCDNA4 myc/his CTPS1-FLAG digested with Not1 and Eco N1.
Site-directed mutagenesis was done using Quickchange™ (Stratagene) per manufacturers
instructions. All mutations were verified by sequencing. Of note, S571 was found to be an
isoleucine in the IMAGE clone and was mutated back to the wild type serine.
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2.16 c-Myc Adenovirus Infection
c-Myc adenovirus was added to MEFs in media without serum, to give a final
concentration of 100 MOI. Expression was allowed to proceed from 24 hours and then
media was replaced with media containing 10% FBS or 0.1% FBS.
CHAPTER
3. Phosphorylation Regulation of Human CTPS1
3.1 Abstract
Cytidine triphosphate synthetase (CTPS) catalyzes the rate-limiting step in the de
novo synthesis of CTP and both the yeast and human enzymes have been reported to be
regulated by PKA or PKC phosphorylation. Here, we provide evidence that stimulation or
inhibition of PKA or PKC does not alter the phosphorylation of endogenous human CTPS1
in HEK 293 cells under the conditions tested. Unexpectedly, we found that low-serum
conditions increased phosphorylation of endogenous CTPS1 and this phosphorylation was
inhibited by the GSK3 inhibitor, indirubin-3’-monoxime, and GSK3 short interfering RNAs
demonstrating the involvement of GSK3 in phosphorylation of endogenous human CTPS1.
Separating tryptic peptides from [32P]-orthophosphate labeled cells and analyzing the
phosphopeptides by mass spectrometry identified S574 and S575 as phosphorylated residues.
Mutation of S571 demonstrated that S571 was the major site phosphorylated by GSK3 in
intact HEK 293 cells by GSK3 in vitro. Furthermore, mutation of S575 prevented the
phosphorylation of S571 suggesting that phosphorylation of S575 was necessary for priming
the GSK3 phosphorylation S571. Low-serum was found to decrease CTPS1 activity and
incubation with the GSK3 inhibitor, indirubin-3’-monoxime, protected against this decrease
in activity. Incubation with alkaline phosphatase increased CTPS1 activity in a time-
dependent manner demonstrating that phosphorylation inhibits CTPS1 activity. Since many
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other phosphorylation sites in the carboxyl terminus of hCTPS1 are CK I consensus
phosphorylation sites and GSK3 and CK I can coordinately phosphorylate other substrates
(e.g. -catenin), we investigated whether CK I was also involved in hCTPS1
phosphorylation. Indeed, using the CK I inhibitor, D4476, CK I was found to be involved in
hCTPS1 phosphorylation and contributed to the phosphorylation of multiple sites in the
carboxy terminus of hCTPS1. This is the first study to investigate the phosphorylation and
regulation of human CTPS1 in human cells and suggests that GSK3 is a novel regulator of
CTPS activity and CK I may also be involved in regulating human CTPS1 function.
3.2 Introduction
Pyrimidine nucleotides have been known for decades to be essential components of
cells. Most recently the effects of nucleotides have been revisited and were shown to
regulate apoptosome formation by binding to cytochrome C and constitutively high levels of
nucleotides were shown to inhibit cell cycle progression and the response to DNA damage
(Chabes and Stillman, 2007; Chandra et al., 2006). Of all the nucleotides, the cellular
concentration of cytidine triphosphate (CTP) is the lowest, suggesting that control of CTP
synthesis is tightly regulated (Traut, 1994). CTP is important in DNA/RNA synthesis,
phospholipid synthesis, protein sialylation and N-linked glycosylation, which are needed for
cell proliferation and cell size expansion. CTP levels are elevated during S phase of the cell
cycle and rapidly proliferating cells maintain a higher basal concentration of CTP and dCTP
(de Korte et al., 1987a; De Korte et al., 1986; de Korte et al., 1987b; de Korte et al., 1985;
Harmenberg et al., 1990; Shewach, 1992; Sidi et al., 1985). Cytidine nucleotide levels were
also found to be elevated in a variety of tumors and elevated, albeit to a lesser degree, in
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normal proliferating cells (van den Berg et al., 1993; van den Berg et al., 1994). Primary
human lymphocytes demonstrate a dramatic increase in CTP levels following mitogenic
stimulation, demonstrating the importance of CTP synthesis in response to growth stimuli
(van den Berg et al., 1994).
Cytidine triphosphate synthetase (CTPS; EC: 6.3.4.2) catalyzes the rate-limiting step
in the de novo formation of CTP; in mammalian cells CTPS catalyzes the amination of UTP
to form CTP with glutamine serving as the amine donor and ATP being hydrolyzed during
the process. The unique ability of CTPS to bind four nucleotides (UTP, ATP, GTP and CTP)
and the amino acid glutamine makes CTPS sensitive to the metabolite levels of four
nucleotides and glutamine in cells, providing exquisite metabolic control of CTPS (Discussed
in more detail in Chapter 1).
Regulation of yeast CTPS by phosphorylation was discovered by Carman and
colleagues who showed that yeast CTPS1 (URA7) was phosphorylated in vitro on multiple
sites by protein kinase C (PKC) (S36, S330, S354, and S454) (Park et al., 2003). Mutation of
potential phosphorylation sites demonstrated that S330 was a major site of PKC
phosphorylation (Park et al., 2003). Additionally, they identified S424 as an in vitro protein
kinase A (PKA) phosphorylation site (Park et al., 1999). The S424A mutant showed
decreased CTPS activity and greater sensitivity to CTP feedback inhibition (Park et al.,
1999). Recently this same group also showed that human CTPS1 expressed in yeast was
phosphorylated by PKA (Han et al., 2005). However, sequence alignment of the yeast
CTPS1 phosphorylation sites with mouse and human CTPS1 indicate that only two of the
phosphorylation sites identified in yeast CTPS1 (URA7) are conserved in humans (Figure
60
3.1), suggesting that human CTPS1 in human cells may be phosphorylated on different sites
than URA7.
Despite the importance of CTP in processes such as phospholipid synthesis and
protein sialylation, little is known about the regulation of human CTPS1. The objective of
this study was to investigate the phosphorylation and regulation of mammalian CTPS1
expressed in mammalian cells.
3.3 Results
3.3.1 PKA and PKC are not Involved in the Phosphorylation of hCTPS1 in Human Cells
CTPS from S. cerevisiae (URA7) was shown to be phosphorylated by PKA and PKC.
However, amino acid sequence alignment of the phosphorylated residues in URA7 with the
corresponding residues of human and mouse CTPS1 and CTPS2, showed that only two of the
five residues are conserved in mammals (Figure 3.1). If PKA and/or PKC was involved in
phosphorylating endogenous hCTPS1 in HEK 293 cells, the phosphorylation site would most
likely not correspond to the sites identified in S. cerevisiae given that many of these sites are
not conserved in mammals. To test whether PKA or PKC are involved in phosphorylation of
endogenous hCTPS1, HEK 293 cells were labeled with [32P]orthophosphate and then PKA or
PKC were activated or inhibited. Activation of PKA by the cAMP elevating agent, forskolin,
alone or in combination with the phosphodiesterase inhibitor (PDE) IBMX did not alter the
phosphorylation of hCTPS1 despite the activation of PKA as assessed by in vitro kinase
assay using KEMPtide as a substrate (Figure 3.2). Inhibition of PKA with up to 20 µM of
the PKA inhibitor, H89, also did not alter hCTPS1 phosphorylation in HEK 293 cells (Figure
3.2). PKC was activated by the addition of the diacylglycerol analog PMA, which activated
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PKC resulting in the increase in phosphorylation of ERK, but did not alter the
phosphorylation of hCTPS1 in HEK 293 cells (Figure 3.3).
Inhibition of PKC with 10 µM Gö6983, which inhibits several PKC isozymes
(Gschwendt et al., 1996; Stempka et al., 1997; Wang et al., 1998), also did not change the
phosphorylation of endogenous hCTPS1 in HEK 293 cells (Figure 3.3). These results
suggest that PKA and PKC are not involved in the phosphorylation of endogenous hCTPS1
in HEK293 cells under the conditions tested. While PKA and/or PKC may contribute to the
phosphorylation of minor sites in hCTPS1 our results do not support a major role for these
kinases in phosphorylating CTPS1.
3.3.2 GSK3 Regulation of Human CTPS1
3.3.2.1 Low-serum induces phosphorylation of endogenous hCTPS1 in a GSK3
dependent manner
Since inhibition or activation of PKA or PKC did not alter the phosphorylation of
endogenous human CTPS1 from [32P]orthophosphate labeled HEK 293 cells (Figure 3.2 and
3.3) we investigated other conditions that could affect CTPS phosphorylation (Table 3.1). In
our search of stimuli and kinases that influence phosphorylation of endogenous hCTPS1 in
HEK 293 cells, we observed that CTPS1 phosphorylation increased after incubation
overnight in low-serum (0.1% FBS). The average increase in radioactivity associated with
endogenous CTPS1 isolated from [32P]orthophosphate labeled HEK 293 cells in 0.1% FBS
was approximately twice that from cells maintained in 10% FBS.
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Figure 3.1 Sequence Alignment of Phosphorylation Sites Identified in Yeast
Human (Homo sapiens), mouse (Mus musculus), yeast (Saccharomyces cerevisiae)
CTPS1 and CTPS2 protein sequences (NCBI accession numbers respectively, NP_001896,
Q9NRF8, P70698, P70303, P28274, P38627) were aligned using Clustal X. The indicated
yeast phosphorylation sites, using the yeast numbering system, and the surrounding
sequences are shown.
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Figure 3.2 Activation or Inhibition of PKA does not Alter CTPS1 Phosphorylation
(A) HEK 293 cells were metabolically labeled with [32P]orthophosphate as described
in “Experimental Procedures”. Cells were treated with DMSO vehicle, 20 µM Forskolin
(FSK) for 15 minutes or 20 µM FSK + 100 µM IBMX for 15 minutes. Immunoprecipitated
CTPS1 was resolved by SDS-PAGE, transferred to nitrocellulose and phosphorylated CTPS1
was visualized by phosphorimage analysis. Normalized CPM refers to the CPM from each
excised protein normalized to the total protein as determined by densitometry. (B) PKA
activity was assessed using KEMPtide as the substrate in an in vitro kinase assay as
described previously (Kemp et al., 1977). (C) For PKA inhibition, 5 µM H89 was added to
HEK 293 cells during the last two hours of [32P]orthophosphate labeling. 20 µM H89 also
did not alter CTPS 1 phosphorylation (data not shown).
A B C
64
Figure 3.3 Activation or Inhibition of PKC does not alter CTPS1 Phosphorylation
(A) Following [32P]orthophosphate labeling, HEK 293 cells were stimulated with
100 ng/ml PMA for 15 minutes or vehicle control. Activation of PKC was determined by
immunoblotting for phosphorylated ERK (Thr202/Tyr204). (B) HEK 293 cells were labeled
with [32P]orthophosphate as described in “Experimental Procedures” and treated with 3 µM
Go6983 in the presence of 10% FBS or 0.1% FBS. CTPS1 was immunoprecipitated,
resolved by SDS-PAGE, transferred to nitrocellulose and phosphorylated CTPS1 was
visualized by autoradiography as described in legend for Figure 3.2.
A B
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Table 3.1 Table of Activators, Inhibitors and Stimuli that do not greatly Affect CTPS1
Phosphorylation
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Two-dimensional thin layer chromatography (2D TLC) separation of tryptic peptides
from endogenous CTPS1 revealed five major phosphopeptide spots and consistent with the
effects of low-serum on CTPS phosphorylation, all five of these spots increased after serum
starvation (Figure 3.4 A).
Since we observed that phosphorylation of CTPS1 increased in low-serum (0.1%
FBS) conditions, kinases known to be activated under these conditions were investigated.
Two kinases shown to be activated under low-serum/nutrient starvation conditions are AMP-
activated protein kinase (AMPK) and glycogen synthase kinase 3 (GSK3) (Munday et al.,
1991),(Welsh et al., 1994). Incubation of HEK 293 cells with the AMPK inhibitor,
compound C, failed to inhibit the increase in CTPS1 phosphorylation induced by low-serum
(data not shown). Analysis of GSK3 demonstrated that the inhibitory phosphorylation site on
GSK3 / (Ser21, Ser9 respectively) was decreased in 0.1% FBS, indicating that GSK3 was
more active when HEK 293 cells were maintained overnight in low serum (Figure 3.4 B). To
test whether GSK3 was involved in CTPS1 phosphorylation, HEK 293 cells were incubated
with the GSK3 inhibitor indirubin-3’-monoxime (indirubin) or the vehicle (DMSO)
overnight in the presence of 10% FBS or 0.1% FBS. The increase in low-serum induced
CTPS1 phosphorylation was inhibited by indirubin, suggesting GSK3 was a candidate kinase
necessary for the phosphorylation of CTPS1 (Figure 3.4 C). Furthermore, two-dimensional
phosphopeptide mapping showed that indirubin decreased the radioactivity of the five
phosphopeptide spots equally (Figure 3.4 C). To further establish that GSK3 was
specifically involved in low-serum induced CTPS1 phosphorylation, GSK3 protein
expression was specifically reduced by small interfering RNA (siRNA) (Figure 3.4 D).
GSK3 siRNA almost completely eliminated GSK3 expression, but did not effect GSK3
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expression (Figure 3.4 D). Analysis of CTPS1 phosphorylation in these cells demonstrated
that low-serum induced CTPS1 phosphorylation was inhibited in cells transfected with
GSK3 siRNA compared to cells transfected with non-targeting siRNA (Figure 3.4 D).
Although much of the low-serum induced CTPS1 phosphorylation was inhibited by
GSK3 siRNA, the low-serum induced CTPS1 radioactivity was not reduced as significantly
as that observed after indirubin treatment (Figure 3.4 C and D), suggesting that GSK3 may
also contribute to the phosphorylation of CTPS1.
3.3.2.2 Identification of S574 and S575 as hCTPS1 phosphorylation sites in intact cells
To identify the amino acids phosphorylated in endogenous CTPS1, HEK 293 cells
were labeled with [32P]orthophosphate and CTPS1 was isolated by immunoprecipitation.
Tryptic peptides from endogenous CTPS1 were separated by 2D TLC and the five
phosphopeptide spots routinely observed were scraped, the peptides eluted and analyzed by
nano-electrospray ionization tandem mass spectrometry (nano-ESI-MS/MS). Spot 3 was
identified as a C-terminal tryptic peptide (SGSSS*PDSEITELK, “*” denotes
phosphorylation) containing a phosphorylation on serine 575 (S575) (Figure 3.5 A). Spots 1
and 5 were identified as the same peptide isolated but the MS/MS data was consistent with a
doubly phosphorylated peptide (SGSS*S*PDSEITELK), S574 and S575 (Figure 3.5 A). The
phosphopeptides were not identified from spots 2 and 4 possibly because the abundance of
the phosphopeptide was too low, the ionization of these peptides was poor or other peptides
in the sample caused ion suppression. Analysis of the S574A mutant showed decreased
intensity of spot 1 (Figure 3.5 B) substantiating the identification of this spot as a tryptic
peptide containing phosphorylated S574 and S575.
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Figure 3.4 Involvement of GSK3 in phosphorylation of endogenous human CTPS1
(A) HEK 293 cells were maintained in 0.1% or 10% FBS overnight and then labeled
with [32P]orthophosphate containing 0.1% or 10% FBS. Lysates were prepared and CTPS1
immunoprecipitated as described in “Experimental Procedures”. Immunoprecipitated CTPS1
was separated by SDS-PAGE, transferred to nitrocellulose and exposed to X-ray film.
Autoradiograph and two-dimensional TLC separation of tryptic peptides are representative of
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four experiments. Total CTPS1 was visualized by MemCode staining the nitrocellulose
membrane. Fold-change bar graph uses data from four experiments (n=4) (B) To determine
the status of GSK3 activation, serine 9 phosphorylation of GSK3 was assessed by
immunoblotting lysates from [32P]orthophosphate labeled HEK 293 cells maintained
overnight in 10% or 0.1% FBS. Lysates were prepared as described in “Experimental
Procedures”. (C) HEK 293 cells maintained overnight in 10% or 0.1% FBS in the presence
of vehicle (DMSO) or 10 µM indirubin-3-monoxime were [32P]orthophosphate labeled as
described in “Experimental Procedures”. Cells were lysed, CTPS1 immunoprecipitated and
visualized as in Fig. 1A. Radioactivity associated with CTPS1 was determined by excising
the corresponding CTPS1 band, Cerenkov counting radioactivity and adjusting the counts per
minute (CPM) for protein amount as described in “Experimental Procedures”. CTPS1 bands
were trypsin digested and two-dimensional thin layer chromatography was performed as
described in “Experimental Procedures”. (D) HEK 293 cells were transfected with the
indicated SmartPool RNA duplexes from Dharmacon as described in “Experimental
Procedures”. Two days following transfection of RNA duplexes, media was switched to
0.1% FBS overnight and cells were labeled the following day with [32P]orthophosphate.
CTPS1 was immunoprecipitated, separated and visualized as described in Fig. 1C. Two-
dimensional thin layer chromatography was also performed as described in Fig. 1C.
Reduction in GSK3 protein expression was assessed by immunoblotting with an antibody
that recognizes total GSK3 and GSK3.
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Figure 3.5 Identification of S574 and S575 as Phosphorylation Sites in Human CTPS1
and Involvement of S574 and S575 in GSK3 Phosphorylation of CTPS1.
(A) HEK 293 cells were labeled with [32P]orthophosphate as described in
“Experimental Procedures” and CTPS1 was immunoprecipitated and visualized as described
in Fig. 1C. Trypsinized endogenous CTPS1 peptides were subjected to two-dimensional thin
layer chromatography as described previously. Radioactive spots observed on
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autoradiograph from TLC plates were scraped. Phosphopeptides eluted from TLC plate
backing and subjected to nano-ESI MS/MS for identification as described in “Experimental
Procedures”. (B) Wild type (WT) FLAG-CTPS1 and indicated FLAG-CTPS1
phosphorylation site mutants were immunoprecipitated using anti-FLAG resin from
transfected HEK 293 cells labeled with [32P]orthophosphate and separated by SDS PAGE.
Following transfer to nitrocellulose, bands corresponding to FLAG-CTPS1 were excised and
radioactivity was counted using Cerenkov counting. Peptides eluted from trypsinized FLAG-
CTPS1 WT and phosphorylation site mutants were separated using two-dimensional thin
layer chromatography as described in “Experimental Procedures”. (C) WT FLAG-CTPS1 or
FLAG-CTPS1 phosphorylation site mutants expressed in HEK 293 cells were
immunoprecipitated using anti-FLAG resin as described in “Experimental Procedures”.
Endogenous CTPS1 was immunoprecipitated as detailed in “Experimental Procedures”.
Endogenous CTPS1 and immunoprecipitated FLAG-CTPS1 was used as substrates in an in
vitro GSK3 kinase reaction as detailed in “Experimental Procedures”. Following the in
vitro GSK3 kinase reaction, endogenous CTPS1 and indicated FLAG-CTPS1 proteins were
separated by SDS PAGE, transferred to nitrocellulose and visualized by autoradiography.
Radioactivity associated with CTPS1 was determined as in Fig. 1C. Endogenous CTPS1 and
FLAG-CTPS1 proteins were trypsin digested and tryptic peptides were subjected to
separation by two-dimensional thin layer chromatography as described in “Experimental
Procedures”.
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The S575A mutant showed decreased intensity of all the spots, except for spot 3
which was barely detectable, suggesting that S575 was a major phosphorylation site and/or
that it was required to “prime” for additional phosphorylations (Figure 3.5 B). Mutation of
S574, S575 or both S574/S575 to alanine (S574A, S575A S574A/S575A) significantly
decreased the amount of radioactivity associated with CTPS1 compared to wild type (WT)
CTPS1 (Figure 3.5 B). Mutation of both S574 and S575 to alanines almost completely
eliminated the radioactivity associated with CTPS1 indicating that S574 and S575 are two
major phosphorylation sites in CTPS1 (Figure 3.5 B).
3.3.2.3 Requirement of S574 and S575 for phosphorylation of hCTPS1 by GSK3
directly
To determine whether GSK3 could phosphorylate S574 and/or S575 directly,
CTPS1 or the indicated phosphorylation site mutants were immunoprecipitated and used as
substrates in an in vitro kinase reaction with GSK3 (Figure 3.5 C). Both endogenous and
transfected CTPS1 were found to be substrates for GSK3 whereas by contrast the S574A,
S575A and the S574A/S575A mutants all showed greatly reduced phosphorylation by
GSK3. This data showed the ability of GSK3 to phosphorylate CTPS1 and indicated that
S574 and, to a greater extent, S575 were necessary for the direct phosphorylation of CTPS1
by GSK3 (Figure 3.5 C). Additionally, these phosphopeptides were separated by 2D TLC
to generate phosphopeptide maps and the pattern of spots compared to the pattern observed
from CTPS1 phosphorylated in intact cells (compare phosphopeptide maps from Figure 3.4
A to phosphopeptides maps from Figure 3.5 C). This data strongly suggested that GSK3
was directly phosphorylating CTPS1 on sites similar to those observed in vivo.
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3.3.2.4 Identification of S571 as a hCTPS1 phosphorylation site in intact cells
GSK3 is a hierarchal kinase that requires prior phosphorylation of a serine/threonine
(S/T) at a position n+4 from the GSK3 phosphorylation site (GSK3 consensus sequence, S/T-
XXX(S/T-Phospho), X is any amino acid) (Fiol et al., 1988). The large decrease in
phosphorylation observed with the mutation S575A, both in intact cells and in vitro with
GSK3, implicates S575 as a critical residue involved in GSK3 phosphorylation of CTPS1.
However whether S575 is serving as the actual GSK3 phosphorylation site or the priming site
for GSK3 phosphorylation of S571 could not be determined from the results in Figure 3.5.
To determine whether the negative charge of the glutamate at residue 579 (E579) was serving
as a phosphomimetic residue and priming for GSK3 phosphorylation of S575, this glutamate
was mutated to alanine (E579A). Analysis of the E579A mutant in intact HEK 293 cells
showed that mutation of this residue did not affect phosphorylation of CTPS1 demonstrating
that E579 does not prime for GSK3 phosphorylation of S575 in intact cells (Figure 3.6).
Another possibility was that phosphorylation of S575 could prime for GSK3 phosphorylation
of S571. Interestingly, the CTPS1 clone we received from the IMAGE consortium contained
a mutation of S571 to an isoleucine (S571I). To address whether S571 was a
phosphorylation site in CTPS1 in intact cells, the S571I mutation was expressed in HEK 293
cells labeled with [32P]orthophosphate. Following isolation by anti-FLAG
immunoprecipitation, the CTPS1 S571I mutant had substantially less radioactivity associated
with it compared to WT CTPS1-FLAG, indicating that S571 was required for CTPS1
phosphorylation (Figure 3.7 A). The combined mutation of S575 and S574/S575 to alanine
with S571I decreased the radioactivity associated with CTPS1 suggesting that S575 was
another major site labeled under these conditions (Figure 3.7 A).
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Figure 3.6 E579A Mutation of CTPS1 does not Alter CTPS1 Phosphorylation
HEK 293 cells were transfected with the indicated DNA, labeled with
[32P]orthophosphate and Flag-tagged CTPS1 was isolated as described earlier in the legend to
Figure 3.5. Radioactivity (CPM) associated with each protein was normalized to total
protein observed by densitometry.
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2D TLC revealed that when S571 was mutated to an isoleucine, the majority of
radioactive spots were diminished, with the exception of one prominent spot (Figure 3.7 A).
This phosphopeptide spot did not disappear when S574 was mutated to alanine in
combination with S571I, but was absent from the S571I/S575A double mutant, indicating
that the phosphopeptide that gives rise to this spot is dependent on S575 being
phosphorylated (Figure 3.7 A). Because serine 571 is mutated to a more hydrophobic
residue, (isoleucine), phosphorylated peptides containing this isoleucine would migrate
further in the second dimension of the two-dimensional phosphopeptide map but maintain
approximately the same migration distance in the first dimension. This suggests that the
prominent radioactive spot observed when S571 was mutated to an isoleucine most likely
corresponds to spots 2 or 3. Consistent with this, spot 3 was identified earlier as the same
tryptic peptide containing unphosphorylated S571 and singly phosphorylated S575 (See
Figure 3.5 A).
3.3.2.5 Involvement of S571 in the phosphorylation of hCTPS1 by GSK3 directly
To determine whether S571 was a substrate for direct phosphorylation by GSK3; WT,
S571I, S571I/S574A, S571I/S575A and S571I/S574A/S575A were used as substrates in an
in vitro kinase reaction with GSK3. Incubation with GSK3 increased the phosphorylation
of WT CTPS1 whereas the phosphorylation of S571I was significantly lower, demonstrating
that S571 was indeed a phosphorylation site for GSK3 (Figure 3.7 B).
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Figure 3.7 Identification of S571 as a Phosphorylation Site in Human CTPS1 and
Involvement of S571 in GSK3 Phosphorylation of CTPS1
(A) As in Fig. 1B, HEK 293 cells were transfected with the indicated DNA.
Following [32P]orthophosphate labeling of cells, radiolabeled CTPS1 protein was
immunoprecipitated, separated by SDS PAGE, transferred to nitrocellulose and visualized
either by autoradiography or phosphorimage analysis. Tryptic peptides were separated by
two-dimensional thin layer chromatography as described in “Experimental Procedures”. (B)
As in Fig. 2C, WT FLAG-CTPS1 and indicated FLAG tagged CTPS1 phosphorylation site
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mutants were used as substrates in an in vitro GSK3 kinase reaction. In vitro GSK3
phosphorylation of WT and CTPS1 phosphorylation site mutants were analyzed by
autoradiography, Cerenkov counting and two-dimensional thin layer chromatography as
described in Fig. 2C. Unlike in Fig. 2C only a quarter of the isolated peptides were loaded
onto the TLC plate to avoid overloading the plate with radioactivity. “*” indicates a non-
specific immunoprecipitated protein observed in the autoradiograph migrating just below
FLAG-CTPS1. Arrow indicates FLAG-CTPS1.
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Analysis of the S571I/S574A phosphorylation site mutant did not show altered incorporation
of phosphate compared to S571I alone, but analysis of S571I/S575A slightly elevated the
amount of phosphate incorporated into CTPS1 compared to S571I, suggesting that without
the ability to phosphorylate S571 or S575 in vitro, GSK3 may phosphorylate an alternative
site, albeit to a much lesser extent.
Analysis of the triple mutant S571I/S574A/S575A showed a slight decreased in the
amount of phosphate incorporated into CTPS1 compared to S571I/S575A suggesting that
S574 may serve as a minor secondary site for GSK3 phosphorylation in vitro (Figure 3.7
B). Separation of phosphorylated peptides from the in vitro GSK3 kinase reaction by 2D
TLC demonstrated that spots 1 and 5 were the most intense (See arrow in Figure 3.7 B).
Although, we previously found the doubly phosphorylated (S574 and S575) peptide in these
two spots, this does not preclude the co-migration of other phosphorylated peptides, in
particular phosphorylated peptides that are not as easily detected using mass spectrometry,
such as a large multiply phosphorylated peptide similar to the one that would be generated if
S571 was phosphorylated. As expected, mutation of S571 to isoleucine (S571I) abolished
the appearance of this spot (see arrow in Figure 3.7 B), demonstrating that this spot contains
phosphorylated S571 and that S571 is the major site in CTPS1 for GSK3. Since the
phosphorylation of CTPS1 was performed in vitro, only sites phosphorylated by GSK3
would incorporate radioactivity, other residues phosphorylated prior to the in vitro kinase
reaction may still be phosphorylated but not labeled with radioactivity. Since GSK3
requires priming phosphorylation, this spot (arrow in Figure 3.7 B) contains a peptide with at
least two phosphorylated residues, S571 and S575 (Figure 3.7 B). Further mutation of S574,
79
S575 and both S574/S575 to alanine combined with S571I did not change the results
observed with S571I alone, again demonstrating that S571 was the major target of GSK3 in
vitro.
3.3.2.6 Effect of GSK3 and phosphorylation on CTPS1 activity
Most GSK3 substrates are negatively regulated by GSK3 phosphorylation (Beals et
al., 1997; Benjamin et al., 1994; Boyle et al., 1991; Dent et al., 1989; Diehl et al., 1998;
Eldar-Finkelman and Krebs, 1997; Fiol et al., 1988; Hughes et al., 1992; Morfini et al., 2002;
Pulverer et al., 1994; Yost et al., 1996). To examine if CTPS1 activity was regulated by
GSK3 phosphorylation, endogenous CTPS1 was isolated by immunoprecipitation from HEK
293 cells maintained in 10% FBS, 0.1% FBS or 0.1% FBS with the GSK3 inhibitor indirubin
and the amount of CTPS1 activity was assayed. Incubation of cells with low-serum
decreased CTPS1 activity compared to cells incubated with 10% FBS (Figure 3.8 A), and
paralleled the effect of these treatments on CTPS1 phosphorylation. Incubation of cells in
low-serum in the presence of the GSK3 inhibitor, indirubin, preserved CTPS1 activity
(Figure 3.8 A), consistent with GSK3 phosphorylation inhibiting the activity of CTPS1.
To further examine the effect of phosphorylation on CTPS1 activity, CTPS1 was
isolated from low-serum incubated HEK 293 cells by immunoprecipitation, treated for 7.5,
15 or 30 minutes with calf intestinal phosphatase (CIP) and CTPS1 activity was measured
(Figure 3.8 B). CTPS1 was significantly dephosphorylated after 15 minutes of incubation
with CIP as seen by the phosphorimage of total isolated CTPS1 and in the 2D
phosphopeptide map (Figure 3.8 B).
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Figure 3.8 Effect of Serum, Indirubin and Phosphatase Treatment on CTPS1 Activity.
(A) Endogenous CTPS1 was immunoprecipitated from HEK 293 cells maintained
overnight in 10% FBS, 0.1% FBS or 0.1% FBS with 10 µM indirubin (indirubin-3’-
monoxime). CTPS1 activity was determined as described in “Experimental Procedures”.
Statistical analysis was done using one-way ANOVA (95% confidence interval) and a Tukey
posthoc test. P < 0.05 was considered significant and designated by “*”. (B) Endogenous
CTPS1 was immunoprecipitated from HEK 293 cells maintained overnight in 0.1% FBS.
Immunoprecipitated endogenous CTPS1 was treated for the indicated times with 15 Units of
calf intestinal alkaline phosphatase (CIP) or equivalent volume of CIP suspension buffer
(50% glycerol) as a control for 30 minutes as detailed in “Experimental Procedures”.
Following CIP treatment, CTPS1 was washed with 1X CTPS reaction buffer and CTPS
activity was assayed as described in “Experimental Procedures”. Statistical analysis was
done using one-way ANOVA (95 % confidence interval) and a Tukey posthoc test. P < 0.05,
P < 0.01 and P < 0.001 were considered significant and indicated by “*“, “**” and “***”,
respectively. Endogenous CTPS1 from [32P]orthophosphate labeled HEK 293 cells
maintained in 0.1% FBS overnight was immunoprecipitated and treated with CIP or
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equivalent amount of 50% glycerol as a control for 15 minutes. Radioactivity associated
with CIP and control treated endogenous CTPS1 was visualized by phosphorimage. CIP and
control treated CTPS1 was also analyzed by two-dimensional thin layer chromatography as
previously described in Fig. 1C and in detail in “Experimental Procedures”.
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CTPS1 activity increased with the time of incubation with CIP demonstrating that CTPS1
was more active following dephosphorylation of the enzyme (Figure 3.8 B).
3.3.3 Further Regulation of Human CTPS1 by Phosphorylation
3.3.3.1 hCTPS1 is not Phosphorylated by JNK, ERK or During the Cell Cycle
Our results demonstrate that GSK3 phosphorylation of hCTPS1 required a priming
phosphorylation on S575, which is N-terminal to a proline, suggesting a proline-directed
kinase phosphorylated this site. Since many of the processes that use CTP (e.g. DNA/RNA
synthesis, phospholipid synthesis, etc.) are involved in cell proliferation we tested whether
the proline-directed kinases of the MAPK family or the CDK family were involved in
hCTPS1 phosphorylation. To determine whether the MAPK, ERK, was involved in CTPS1
phosphorylation, serum-starved HEK 293 cells were labeled with [32P]orthophosphate and
stimulated with 100 ng/ml epidermal growth factor (EGF) for 10 minutes or pre-treated for 5
minutes with the MEK inhibitor, U0126 (10 µM), prior to EGF stimulation. Despite
activation of ERK by EGF or suppression of ERK activation by pre-treatment with U0126,
phosphorylation of endogenous hCTPS1 was not changed (Figure 3.9). This result was
consistent with a large-scale analysis of phosphorylation sites in HeLa cells stimulated with
EGF where none of the phosphorylation sites identified in hCTPS1 changed with EGF
treatment (Olsen et al., 2006). To investigate whether the MAPK c-Jun N-terminal kinase,
JNK, was involved in hCTPS1 phosphorylation, HEK 293 cells labeled with
[32P]orthophosphate were stimulated with anisomycin, a JNK activator, and the
phosphorylation of hCTPS1 was assayed as described earlier.
83
Figure 3.9 ERK is not Involved in hCTPS1 Phosphorylation
HEK 293 cells were maintained in 0.1% FBS overnight and then stimulated with 100
ng/ml EGF in the presence or absence of the MEK inhibitor U0126 (10 µM).
Phosphorylation of CTPS1 was analyzed as described in “Experimental Procedures”.
Activation of ERK was assessed by immunoblotting for phosphorylation of Thr202/Tyr204
on ERK. Normalized CPM described in legend for Figure 3.2.
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Figure 3.10 JNK is not Involved in hCTPS1 Phosphorylation
HEK 293 cells were labeled with [32P]orthophosphate and then stimulated with 10
µg/ml anisomycin or DMSO for 1 hour. For SP600125 treatment, HEK 293 cells were
maintained in 0.1% FBS overnight in the presence of 10 µM SP600125 or DMSO and
labeled with [32P]orthophosphate. Phosphorylation of CTPS1 was assessed as described in
“Experimental Procedures”. JNK activity was assessed by immunoblotting for the
phosphorylation of c-Jun (Ser73), a JNK substrate.
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Despite activation of JNK as shown by phosphorylation of c-Jun, no change in the
phosphorylation of hCTPS1 was observed (Figure 3.10).
To further determine if JNK was involved in the low-serum induced phosphorylation,
cells were incubated overnight in the absence or in the presence of the JNK inhibitor
SP600125 (10 µM). Incubation with the JNK inhibitor did not alter hCTPS1
phosphorylation indicating that JNK was not involved in low-serum induced phosphorylation
and unlikely to be necessary for priming phosphorylation on S575 (Figure 3.10).
The involvement of cell cycle-dependent kinases, CDKs, was investigated by
synchronizing HeLa cells using double thymidine block and [32P]orthophosphate labeling
cells. Although HeLa cells were synchronized as observed by cyclin A protein levels,
CTPS1 phosphorylation did not change throughout the cell cycle (Figure 3.11). Furthermore,
treatment of [32P]orthophosphate labeled HEK293 cells with the CDK inhibitors roscovitine
and olomoucine (data not shown) did not alter hCTPS1 phosphorylation indicating that
CDKs 1, 2 do not seem to be involved in the phosphorylation of hCTPS1.
3.3.3.2 Involvement of CK I in hCTPS1 Phosphorylation
All of the phosphorylation sites of hCTPS1 in the Phosida database are confined to
the C-terminal 35 amino acids of the protein and contain many consensus CK I
phosphorylation sites (Flotow et al., 1990; Olsen et al., 2006). To test whether CK I is
involved in the phosphorylation of hCTPS1, HEK 293 cells were labeled with
[32P]orthophosphate and either maintained in 10% or 0.1% serum in the presence or absence
of the CK I inhibitor D4476.
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Figure 3.11 hCTPS1 Phosphorylation is not Altered During the Cell Cycle
HeLa cells were synchronized by double thymidine block and 2 hours prior to
harvesting cells, cells were labeled with [32P]orthophosphate. Phosphorylation of CTPS1
was determined by determining the relative density of the autoradiograph to the
corresponding amount of total CTPS1. Synchronization of the cell cycle was ascertained by
immunoblotting for cyclin A. Total amount of protein was determined by immunoblotting
for -actin.
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Figure 3.12 Inhibition of CK I Reduces Phosphorylation of hCTPS1
(A) HEK 293 cells were maintained in 10% or 0.1% FBS overnight in the presence
or absence of the CK I inhibitor D4476 (50 µM). Following [32P]orthophosphate labeling of
HEK 293 cells, CTPS1 was isolated as described in “Experimental Procedures”. Shown is
the radioactivity of CTPS1 normalized to total amount of CTPS1. (B) Also shown are the
separation of the tryptic peptides by 2D TLC.
A B
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Figure 3.13 CK I Inhibition does not Affect CTPS1 Activity
HEK 293 cells were maintained in 10% or 0.1% FBS overnight in the presence or
absence of the CK I inhibitor, D4476 (50 µM). CTPS1 activity was determined as described
in “Experimental Procedures”.
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The CK I inhibitor D4476 reduced phosphorylation in both 10% and 0.1% maintained HEK
293 cells consistent with the idea that CK I is constitutively active and is involved in
phosphorylating CTPS1 under 10% and 0.1% serum conditions (Figure 3.12). Separation of
tryptic peptides control and D4476 treated HEK 293 cells showed a decrease in intensity of
multiple spots suggesting that CK I phosphorylates hCTPS1 on multiple residues (Figure
3.12). CK I phosphorylation of hCTPS1 on multiple residues is not surprising given the fact
that CK I is a hierarchal kinase that requires a priming phosphorylation or an acidic residue at
the residue n-2 from the CK I phosphorylation site ( (priming-phospho-S/T)XX(S/T-CK I –
phospho)) (Flotow et al., 1990) and that many sites in the C-terminus of hCTPS1 resemble
consensus CK I phosphorylation sites (See Figure 3.14).
3.3.3.3 Inhibition of CK I does not Affect CTPS1 Activity Under the Conditions Tested
To investigate whether CK I was involved in hCTPS1 activity, HEK 293 cells were
maintained overnight in 10% or 0.1% FBS in the presence or absence of the CK I inhibitor
D4476. CK I inhibition did not alter hCTPS1 enzyme activity under the conditions tested
(Figure 3.13) suggesting that if CK I is involved in hCTPS1 phosphorylation it may regulate
a different CTPS function (e.g. localization) or may regulate hCTPS1 under conditions
different from the one it was tested in.
3.4 Conclusions
Although the phosphorylation of both yeast and human CTPS1 expressed in yeast has
been investigated, this is the first investigation of the phosphorylation of human CTPS1 in
human cells. Unlike yeast CTPS1, endogenous human CTPS1 was not phosphorylated by
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PKA or PKC under the conditions examined in this study. This is consistent with the fact
that many of the PKA and PKC sites found in yeast CTPS1, are not conserved in human
CTPS1 (Figure 3.1). Instead our results point to the novel and unexpected phosphorylation
of the carboxy terminus of human CTPS1. None of the putative sites in the carboxy terminus
of human CTPS1 are consensus PKA or PKC sites, consistent with our results. Sequence
alignment of the carboxy termini from various organisms shows how conserved many of the
phosphorylation sites are among mammals, whereas in other eukaryotes they diverge (e.g.
fly, worm, yeast) (Figure 3.14).
The observation that the sequence conservation varies between mammals and D.
melanogastor and C. elegans does not preclude that D. melanogastor and C. elegans are
regulated by phosphorylation on their carboxy terminus, but does suggest that the regulation
of CTPS1 by phosphorylation may be different in these other organisms. The difference
between the carboxy terminus from yeast and human CTPS1 suggests that human CTPS1,
and perhaps nucleotide metabolism, is regulated differently in humans than in yeast. S571 is
highly conserved in all the mammalian sequences examined and is even conserved in CTPS2
indicating the potential importance of this residue in the phosphorylation of this isoform.
In human and mouse CTPS, S575 is found only in CTPS1 and not in CTPS2 whereas,
in both CTPS1 and CTPS2 from other mammals, position 575 is conserved. The ability of
position 575 to be phosphorylated in both CTPS1 and CTPS2 from other mammals may
indicate a more redundant role for CTPS1 and CTPS2 in these organisms whereas the ability
of S575 to be phosphorylated only in human and mouse CTPS1, but not CTPS2, suggests
different roles for CTPS1 and CTPS2 in humans and mice.
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Multiple lines of evidence point to the role of GSK3 to phosphorylate and regulate
CTPS1. Inhibition of GSK3 with the inhibitor indirubin and siRNA, revealed that GSK3 was
involved in the low-serum induced phosphorylation of endogenous human CTPS1. Mutation
of S575 to alanine inhibited much of the radioactivity associated with CTPS1 and S575 was
investigated as a direct GSK3 phosphorylation site by mutating the potential priming site,
E579, to alanine (E579A). Since the E579A mutant failed to alter CTPS1 phosphorylation,
S575 was investigated as a priming site for phosphorylation of S571. From these studies it
was concluded that S571 was the major site for GSK3 phosphorylation in vitro.
Interestingly, the CTPS1 clone we received from the IMAGE consortium, derived from a
retinitis pigmentosa cell line contained a naturally occurring mutation of S571 to isoleucine
(S571I), which suggests that phosphorylation of S571 may play a role in diseases such as
retinitis pigmentosa. The kinase responsible for phosphorylation of S575 was not identified
despite investigation of a variety of well known proline directed kinases (e.g. ERK, JNK and
CDKs, Figures 3.9, 3.10, 3.11).
GSK3 was originally identified as the third kinase responsible for the phosphorylation
of glycogen synthase, which decreased glycogen synthase activity (Embi et al., 1980; Rylatt
et al., 1980). Since this seminal discovery, multiple substrates and cellular roles of GSK3
have been elucidated. Many GSK3 substrates identified are involved in metabolism (e.g.
glycogen synthase, acetyl CoA carboxylase, insulin receptor substrate, pyruvate
dehydrogenase) demonstrating a prominent role for GSK3 in regulating metabolism
(reviewed in (Frame and Cohen, 2001)).
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Figure 3.14 Carboxy terminus sequence alignment of CTPS1 and CTPS2 from various
organisms.
Clustal X was used to align the carboxy terminus of CTPS1 and CTPS2 from a
variety of organisms. S571, S574 and S575 are indicated. Box designates the tryptic
peptide identified in this study. The sequences used are as follows (NCBI Accession
number): H. sapiens CTPS1 (NP_001896), H. sapiens CTPS2 (Q9NRF8), M. musculus
CTPS1 (P70698), M. musculus CTPS2 (P70303), B. rerio CTPS1 (NP_954681), B. rerio
CTPS2 (XP_001341091), T. nigroviridis CTPS (CAG00263), G. gallus CTPS1
(XP_417709), G. gallus CTPS2 (Q5F3Z1), D. melanogastor CTPS isoform C (NP_730023),
C. elegans CTPS1 (CAA16517), C. elegans CTPS2 (CAD21649), S. pombe (CAA15716), S.
cerevisiae CTPS1 (P28274), S. cerevisiae CTPS2 (P38627).
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The decrease in CTPS1 activity by GSK3 is consistent with GSK3 negatively
regulating the function other known GSK3 substrates (e.g. glycogen synthase, -catenin,
pyruvate dehydrogenase) and supporting the role of GSK3 phosphorylation as catalyzing
inhibitory events. Interestingly, the carboxy-terminus of mammalian CTP: phosphocholine
cytidylyl transferase (CCT, EC: 2.7.7.15), which is the rate-limiting enzyme in
phosphatidylcholine biosynthesis and the next biosynthetic step in phospholipid metabolism,
is phosphorylated on multiple sites like CTPS1 (MacDonald and Kent, 1994; Watkins and
Kent, 1991). Moreover CCT activity is decreased by phosphorylation (MacDonald and Kent,
1994; Watkins and Kent, 1991). Multiple phosphorylation sites in the carboxy-terminus of
CCT are GSK3 consensus sites suggesting that phosphatidylcholine, and possibly
phospholipid synthesis in general, may be regulated by GSK3 phosphorylation of rate-
limiting enzymes, such as CCT and CTPS1. In yeast Carman and colleagues demonstrated
the critical role of CTP and CTPS phosphorylation in regulating phospholipid synthesis
(Choi et al., 2003; McDonough et al., 1995; Park et al., 2003) and Mclarty and Hatch showed
CTPS activity is critical for phospholipid synthesis in mammalian cells supporting the notion
that CTP synthesis and phospholipid synthesis could be coordinately regulated (Hatch and
McClarty, 1996). Whether or not these events are coordinated is an interesting possibility
that remains to be explored
Several large-scale analyses of the phosphoproteome have identified numerous
phosphorylation sites in the carboxy-terminus of CTPS1 (S562, T566, Y567, S568, S571,
S573, S574, S575, S578 and T581) (Olsen et al., 2006). Our studies confirmed the
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phosphorylation of S571, S574 and S575. The fact that the other sites were not detected in
our analysis suggests that these sites may be minor phosphorylation sites or were not labeled
under the conditions used in this study. Interestingly, tyrosine phosphorylation was found on
CTPS1 using a anti-phosphotyrosine antibody, but did not to require S571 to be
phosphorylated (data not shown). Phosphoaminoacid analysis of CTPS1 also paralleled the
results of the large-scale phosphoproteome analysis, demonstrating that serine was the most
highly phosphorylated amino acid followed by threonine. Phosphorylation of tyrosine was
below the limits of detection by radioactivity (data not shown). The observation that
multiple phosphorylation sites are clustered in the carboxy-terminus of mammalian CTPS1
suggests that multiple kinases may be involved in phosphorylation regulation of CTPS1,
including other hierarchal kinases such as casein kinase 1 (CK I).
Our investigation of CK I demonstrated that CK I was involved in CTPS1
phosphorylation and inhibition of CK I did not affect CTPS1 activity under the conditions
tested (Figure 3.12). Further investigation of the phosphorylation and regulation of CTPS1
by CK I is needed before we know how CK I is involved in CTPS1 function. One possibility
that remains is that the coordinated action of CK I and GSK3 are necessary for full inhibition
of CTPS1.
The crystal structures of bacterial CTPS have identified conserved amino acids that
are proposed to be necessary for catalysis, dimerization and tetramerization (Endrizzi et al.,
2004; Goto et al., 2004). However, the C-terminal region containing S571, S574 and S575 is
not present in these three-dimensional structures making it difficult to predict exactly how
phosphorylation of the C-terminus affects CTPS activity.
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Figure 3.15 Intracellular Localization of Endogenous, WT, S574A, S575A,
S574A/S575A CTPS1 in HeLa Cells
HeLa cells were fixed, permeabilized, blocked with horse serum plus BSA and then
incubated with primary followed by fluorophore-conjugated secondary antibodies. For
staining of endogenous CTPS1, 1:500 dilution in blocking buffer of -CTPS1 antibody was
used. For staining of transfected CTPS1, 1:300 dilution in blocking buffer of -Flag
antibody was used. Secondary antibody for staining of endogenous CTPS1 was goat-anti-
rabbit Alexa 488 conjugated (1:1000) and the secondary antibody for staining of Flag-tagged
CTPS1 was goat-anti-mouse Alexa 488 conjugated (1:1000) antibody. Cells were visualized
using an Olympus confocal microscope. Detailed procedures can be found in “Experimental
Procedures”.
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Analysis of intracellular localization of S574A, S575A and S574A/S575A CTPS1 in
HeLa cells did not show a robust change in CTPS1 localization suggesting that
phosphorylation does not affect CTPS1 localization under the conditions tested (Figure 3.15).
Analysis of the hydrophobicity/hydrophilicity of human CTPS1 using the Kyte-
Doolittle hydrophobicity scale indicates that the C-terminus is hydrophilic and is most likely
solvent exposed possibly allowing for interaction with proteins that affect CTPS activity.
Phosphorylation of yeast CTPS1 affects activity through altering the tetramerization of
CTPS1 (Pappas et al., 1998) providing a precedent for how phosphorylation of human
CTPS1 may regulate CTPS activity. Phosphorylation of human CTPS1 on the C-terminus
could directly influence tetramerization (e.g. negative charges of phosphate could cause
domains to shift allowing for tetramerization) or phosphorylation of the C-terminus could
affect tetramerization indirectly for instance by recruiting a protein (or displacing a protein)
that alters tetramerization. Both 14-3-3 and WW domain containing proteins such as Pin1
interact specifically with phosphorylated residues and could mediate changes in CTPS1
activity. Interestingly, a large-scale analysis of HeLa cell proteins that interact with 14-3-3
identified CTPS as an interacting protein (Meek et al., 2004). .
GSK3 activity is regulated following a variety of stress stimuli, including serum
withdrawal/nutrient deprivation, and during development through Wnt and Notch signaling
(Welsh et al., 1994) (reviewed in (Marikawa, 2006; Robert and Lallemand, 2006)). Our data
suggests that mammalian CTPS1 may be involved in development and/or physiological
stresses that involve serum/nutrient withdrawal such as stroke or ischemia (Figure 3.16).
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Figure 3.16 Summary Model of CTPS1 Phosphorylation and Possible Impact on CTP-
dependent Processes
(A) When GSK3 is active (Ser9 () or Ser21 () is not phosphorylated) CTPS1 is
phosphorylated by GSK3, inhibiting CTPS1 activity and resulting in decreased CTP levels
and lower activity of CTP-dependent processes. (B) When GSK3 is inactive (Ser9 () or
Ser21 () is phosphorylated) then CTPS1 is less phosphorylated, in particular S571, resulting
GSK3 Inactive
A
B
GSK3 Active
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in increased CTPS1 activity ultimately translating into increased output of CTP-dependent
processes.
CHAPTER
4. Human CTPS1 Interacting Proteins
4.1 Abstract
Many GSK3 phosphorylation targets are known substrates for the peptidyl prolyl
isomerase Pin1, which isomerizes proline bonds juxtaposed to a phosphorylated serine or
threonine Since S575 is a phosphorylated residue next to a proline we tested whether Pin1
was a CTPS1 interacting protein using GST-Pin1 binding assays. CTPS1 was found to
interact with GST-Pin1 in a S575 dependent manner suggesting prolyl isomerization may
regulate CTPS1 function. Since the expression of CTPS1 has not been well characterized,
we investigated CTPS1 expression in various rat tissue extracts and cell lines. We found that
CTPS1 was most highly expressed in brain and liver from rat tissue and HEK 293 cells
expressed the most CTPS1 protein of all the cell lines examined. Differentiation of 3T3 cells
to adipocytes decreased CTPS1 protein expression suggesting CTPS1 expression decreased
during differentiation. Downregulation of c-myc is necessary for 3T3 differentiation into
adipocytes and c-myc has been shown to be required for the expression of the rate-limiting
enzyme, CAD, in the de novo synthesis of uridine nucleotides (Miltenberger et al., 1995;
Pulverer et al., 1994). We therefore, investigated whether c-myc was involved in regulating
CTPS1 expression levels. Immunoblotting for CTPS1 showed that CTPS1 protein levels
were decreased in c-myc-/- cells compared to c-myc+/+ cells. Reintroduction of c-myc into c-
myc-/- cells restored CTPS1 expression implicating c-myc in regulating CTPS1 expression.
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While investigating CTPS1 subcellular localization we noticed that tubulin and CTPS1
colocalized. Treatment with the microtubule polymerizing agent, taxol, appeared to enhance
the colocalization of tubulin and CTPS1. Cotreatment with the CTPS inhibitor, CPEC, and
taxol failed to disrupt the colocalization suggesting that the colocalization was not dependent
on CTPS activity. Investigation using A10 rat smooth muscle cells demonstrated that CTPS1
and tubulin colocalized more strongly during mitosis at what appeared to be the mitotic
spindle. Immunoprecipitation and reciprocal immunoprecipitation verified the interaction
between tubulin and CTPS1. A screen to identify other CTPS1 interacting proteins identified
thirteen other CTPS1 coimmunoprecipitating proteins, many of which were cytoskeletal.
Thus these studies provide novel information into the potential interacting proteins that may
regulate CTPS1 function.
4.2 Introduction
In addition to phosphorylation, enzyme activity can be regulated by protein-protein
interactions. Although, there have been several large scale analyses of protein-protein
interaction networks, these studies relied on ectopically expressed proteins or non-
mammalian organisms such as S. cerevisiae. As observed with the phosphorylation of
CTPS1 (see Chapter 3), mammalian CTPS1 can be regulated differently than CTPS in S.
cerevisiae. We therefore investigated CTPS1 interacting proteins using endogenously
expressed CTPS1 in mammalian cells. Since phospholipid synthesis in mammalian cells has
been shown to be localized to distinct subcellular compartments [20-22] and other pyrimidine
metabolic enzymes have also been shown to have distinct subcellular distribution (e.g.
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uridine phosphorylase with vimentin [23], cytidine deaminase within the nucleus [24]) we
predicted that CTPS1 will interact with a unique subset of proteins
4.3 Results
4.3.1 Pin1 Interacts with CTPS1
Pin1 is a peptidyl prolyl isomerase that recognizes phosphorylated serines or
threonine N-terminal to prolines. Upon binding a phosphorylated serine or threonine, Pin1
catalyzes the cis to trans isomerization of the prolyl peptide bond ((Lu et al., 1996;
Ranganathan et al., 1997). Isomerization of the proline bond in many proteins have been
shown to regulate their function. For instance CDK2, MAPKs and the phosphatase PP2A
prefer their substrates be in trans configuration for catalysis (Brown et al., 1999; Weiwad et
al., 2000; Zhou et al., 2000). Some of the Pin1 targets are known substrates of GSK3 (e.g tau
protein) suggesting that CTPS1 might also be a Pin1 target. Using Xenopus laevis Pin1
attached to GST, GST-xPin1, HEK 293 cell lysates were used to determine whether
endogenous CTPS1 could bind to GST-xPin1. Compared to GST, coimmunoprecipitation
experiments demonstrated that GST-xPin1 and CTPS1 formed a complex with each other
suggesting that Pin1 and CTPS1 can interact (Figure 4.1). To determine if this complex
formation was dependent on S575, GST-xPin1 was incubated with lysate from untransfected
HEK 293 cells or HEK 293 cells transfected with WT or S575A flag-tagged mutant. Under
these conditions, the WT CTPS1 is known to be phosphorylated on S575 whereas the mutant
S575A is not (Chapter 3). The CTPS1 S575A mutant protein showed decreased ability to
interact with GST-xPin1 compared to WT-CTPS1 demonstrating that Pin1 binding was
dependent on S575 phosphorylation (Figure 4.2). The decreased ability of S575A CTPS1 to
interact with Pin1 was not because the GST-xPin1 lost the ability to interact with CTPS1,
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because endogenous CTPS1 interacted with GST-xPin1 as shown (Figure 4.2). To determine
whether Pin1 binding could alter CTPS1 activity, CTPS1 activity was determined from HEK
293 cells transfected with siRNAs directed towards Pin1 or non-targeting siRNA. Despite
significantly decreased protein levels of Pin1 after siRNA treatment, CTPS1 activity was not
affected indicating that, under the conditions tested, Pin1 does not alter activity or protein
stability of CTPS1 (Figure 4.3). However, further experiments to investigate if Pin1 binding
affects CTPS phosphorylation, localization or stability are necessary.
4.3.2 Tubulin is a CTPS1 Interacting Protein
4.3.2.1 Colocalization of Tubulin with CTPS1 in HEK 293 Cells
While investigating the localization of CTPS1 in HEK 293 cells we observed CTPS1
localization suggesting a microtubule specific localization (Figure 4.4). Immunostaining of
HEK 293 cells for endogenous CTPS1 and -tubulin revealed that CTPS1 colocalized with
microtubules as observed by confocal microscopy (Figure 4.4).
4.3.2.2 Colocalization of Tubulin with CTPS1 in Taxol-treated HEK 293 Cells
In an attempt to increase the incidence of observing the colocalization of
microtubules and CTPS1, HEK 293 cells were treated with the microtubule stabilizing agent,
taxol (100 nM, 7 hours). As seen in Figure 4.5, taxol induced the formation of “tufts” of
microtubules and CTPS1 colocalized with these tufts, indicating that under conditions when
microtubules are induced to polymerize, the colocalization of CTPS1 and microtubules is
enhanced.
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Figure 4.1 Endogenous CTPS1 can Interact with GST-xPin1
HEK 293 cells were lysed as described in “Experimental Procedures” and incubated
with approximately 20 µg of GST or GST-xPin1. 2% of the total amount of lysate incubated
with the GST fusion proteins is shown as a comparison. Affinity-precipitated proteins were
washed with lysis buffer, separated by SDS-PAGE and analyzed by immunoblotting for
CTPS1.
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Figure 4.2 S575 is Involved in Pin1 Interacting with CTPS1
HEK 293 cell lysates and analysis was performed as described in the legend to Figure
4.1. Immunoblot analysis involved probing for the Flag tag on transfected CTPS1 where
indicated. Endogenous CTPS1 was immunoblotted for comparison using an antibody
specific for this protein.
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Figure 4.3 Silencing Pin1 Expression with siRNA does not Affect CTPS1 Activity
HEK 293 cells were transfected with Smart Pool™ siRNA per manufacturers
instructions, maintained in 0.1% FBS overnight and activity of CTPS1 was assessed as
described in “Experimental Procedures”. Expression of Pin1 and CTPS1 was assessed by
immunoblot as described in “Experimental Procedures”.
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4.3.2.3 Effect of CPEC and CPEC plus Taxol on Tubulin and CTPS1 Localization
To determine if inhibition of CTPS affected microtubules, HEK 293 cells were
treated with CPEC, a highly specific inhibitor of CTPS. Treatment with CPEC appeared to
increase the size of cell nuclei and also appeared to increase the network of microtubules
(Figure 4.6). Since CPEC can cause cell cycle arrest (Huang et al., 2004), the effects
observed on microtubules may be an indirect cause of inhibition of these cellular processes or
disruption of other CTP-requiring processes.
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Figure 4.4 Immunostaining of CTPS1 and Tubulin in Unstimulated HEK 293 Cells
(A) HEK 293 cells were immunostained with -CTPS1 antibody or -CTPS1
antibody following preabsorption with the antigenic peptide as described in “Experimental
Procedures”. (B) Shown are typical immunostaining of CTPS1 and tubulin in most HEK
293 cells (“Usually Observed”) and immunostaining observed occasionally in some HEK
293 cells. Immunostaining of CTPS1 and tubulin was done as described in “Experimental
Procedures” using Alexa 488 conjugated secondary for staining of CTPS1 and Alexa 594
conjugated secondary for staining anti-tubulin.
A
B
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Figure 4.5 CTPS1 and Tubulin Immunostaining of Taxol-treated HEK 293 Cells
HEK 293 cells were treated with 250 nM taxol for 7 hours prior to fixing cells.
Immunostaining of HEK 293 cells for CTPS1 and tubulin was done as described in
“Experimental Procedures” and legend to figure 4.4.
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Figure 4.6 Immunostaining of CTPS1 and Tubulin in CPEC-treated HEK 293 cells
HEK 293 cells were treated with 100 nM CPEC for 48 hours prior to fixing cells and
immunostaining for CTPS1 and tubulin as described in “Experimental Procedures” and the
legend to figure 4.4.
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We also investigated whether cotreatment with CPEC and taxol would alter the
microtubule architecture and/or CTPS1 colocalization. The cotreatment of HEK 293 cells
with CPEC plus taxol induced the “tufts” of microtubules to form. In cells where “tufts” were
not observed, the microtubule network seemed to be surrounding the enlarged nucleus
(Figure 4.7). CTPS1 colocalized with “tufts” of microtubules in the presence of CPEC plus
taxol and appeared to colocalize with the microtubule network surrounding the nucleus in
cells where the “tufts” were absent (Figure 4.7). The fact that CPEC did not prevent
colocalization of CTPS1 with taxol-induced microtubule “tufts” indicates that CTPS activity
was not required for this colocalization.
4.3.2.4 Colocalization of CTPS1 and Tubulin in Mitotic A10 Rat Smooth Muscle Cells
To determine whether the CTPS1 colocalization with polymerized microtubules
occurs in a cell cycle-dependent manner, A10 rat smooth muscle cells were immunostained
for CTPS1 and -tubulin and cells in interphase and mitosis were visualized. As observed in
Figure 4.8, CTPS1 localized to the cell periphery and areas surrounding the nucleus in
interphase and was not specifically interacting with all the microtubules. However, in
mitosis CTPS1 strongly colocalized with microtubules involved in the formation of the
mitotic spindle, indicating that in mitosis CTPS1 may have a mitotic function involving
microtubules.
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Figure 4.7 Immunostaining of CTPS1 and Tubulin in HEK 293 Cells Treated with
CPEC and Taxol
HEK 293 cells were treated with 100 nM CPEC and 250 nM taxol for 7 hours prior to
fixing cells for immunostaining. CTPS1 and tubulin immunostaining were done as described
in “Experimental Procedures” and the legend to figure 4.4.
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Figure 4.8 Immunostaining of CTPS1 and Tubulin in Interphase and Mitotic A10
Smooth Muscle Cells
A10 rat aortic smooth muscle cells were grown and immunostained as described in
“Experimental Procedures” and in the legend to figure 4.4. Shown are a representative cell
in interphase and a cell in mitosis.
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4.3.2.5 Immunoprecipitation and Reciprocal Immunoprecipitation of CTPS1 and Tubulin
To verify that the colocalization of CTPS1 and tubulin occurred through complex
formation of the two proteins, CTPS1 or tubulin was immunoprecipitated and the reciprocal
protein was immunoblotted for. Immunoprecipitation of CTPS1 from HEK 293 cells showed
that tubulin coimmunoprecipitated with CTPS1. Preabsorbing the -CTPS1 antibody with
the antigenic peptide abrogated this coimmunoprecipitation, indicating this interaction was
CTPS1 dependent (Figure 4.9). Reciprocally, CTPS1 was found to coimmunoprecipitate
with -tubulin, but not with protein-A agarose alone, indicating that the interaction of
immunoprecipitated CTPS1 was -tubulin dependent (Figure 4.9).
4.3.3 Screen for Other CTPS1 Interacting Proteins
The following strategy was used to identify other CTPS1 interacting proteins: 1)
immunoprecipitating CTPS1 from HEK 293 cells using the CTPS1 antibody preabsorbed
with or without the antigenic peptide; 2) separating coimmunoprecipitating proteins by SDS
PAGE; 3) radiolabeling cells with [35S]methionine to probe for interactions radiolabeled
proteins; 4) identifying putative interacting proteins by mass spectrometry.
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Figure 4.9 Immunoprecipitation and Reciprocal Immunoprecipitation of CTPS1 and
Tubulin. Identification of CTPS1 Interacting Proteins by
[35S]Methionine Labeling
(A) Anti-CTPS1 antibody or anti-CTPS1 antibody preabsorbed with antigenic
peptide was used to immunoprecipitate CTPS1 from HEK 293 cells as described previously.
Coimmunoprecipitating proteins were separated by SDS PAGE and -tubulin was visualized
by immunoblot analysis as described in “Experimental Procedures”. Anti--tubulin antibody
or protein A alone was used to immunoprecipitate -tubulin from HEK 293 cell lysates as
described in “Experimental Procedures”. Coimmunoprecipitating proteins were separated by
SDS PAGE and CTPS1 was visualized by immunoblotting for CTPS1. (B) HEK293 cells
were labeled overnight with [35S]methionine and immunoprecipitated (IP) the following day
with anti-CTPS1 antibody or anti-CTPS1 antibody preabsorbed with antigenic peptide.
Immunoprecipitates were separated on a 4-12% acrylamide gel. CTPS1 co-
immunoprecipitating proteins visualized on autoradiograph of dried gel were identified by
MALDI-TOF mass spectrometry.
A B
115
Initially we labeled HEK 293 cells with [35S]methionine to enhance detection of
CTPS1 coimmunoprecipitating proteins. This had the unexpected advantage of labeling a
protein that comigrated on SDS PAGE with the rabbit IgG heavy chain, thereby allowing us
to identify this protein by mass spectrometry. Specifically this was accomplished by gating
the peptide search program to search the human database only (i.e. did not include the rabbit
database since this would undoubtedly identify IgG). This protein was identified as tubulin
(peptides identifying both  and  tubulin were found), and since tubulin and CTPS1 were
both labeled with [S35]methionine, the molar stoichiometry between tubulin and CTPS1 was
estimated to be 1:1. This data strongly suggested that CTPS1 formed a complex with tubulin
and supported our earlier observations. An additional protein identified by this method was
deoxyhypusine synthase, DHS (Figure 4.9).
Further investigation using the same strategy without [35S]methionine, but using
colloidal coomassie staining of the SDS PAGE gel, revealed thirteen coimmunoprecipitating
proteins (Figure 4.10). Included were the rate-limiting enzyme for the de novo synthesis of
uridine pyrimidines, CAD, and many cytoskeletal proteins. The identification of CAD
subunit interacting with CTPS1 in yeast has been observed in a large scale analysis of the
yeast interactome (Gavin et al., 2002) and the number of cytoskeletal proteins
coimmunoprecipitating with CTPS1 is not unexpected due to the interaction of CTPS1 with
tubulin. Interestingly, retinitis pigmentosa like 1 protein (RPL1) was identified as a CTPS1
coimmunoprecipitating protein. The apparent molecular weight (~55 kDa) of RPL1 is
significantly smaller than the predicted molecular weight (~200 kDa), which may indicate
this protein was proteolyzed. The mutation of the GSK3 phosphorylation site in CTPS1,
S571 (See chapter 3), was from a clone derived from a retinitis pigmentosa cell line
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suggesting CTPS1 may play a role in retinitis pigmentosa. Further research is required to
explore this interesting possibility.
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Figure 4.10 Identification of CTPS1 Interacting Proteins (Colloidal Coomassie Stain)
by Mass Spectrometry
CTPS1 was immunoprecipitated with anti-CTPS1 antibody or anti-CTPS1 antibody
preabsorbed with antigenic peptide as described in legend for Figure 4.9. Indicated
coomassie stained protein bands were excised, trypsin digested and identified by peptide
mass fingerprinting (PMF) on a ABI 4700 MALDI TOF/TOF.
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4.3.4 CTPS1 Expression in Extracts from Rat Tissue and Lysates from Cell Lines
Since many of the proposed interacting proteins, most notably tubulin, can be found
in various cell types, it was important to determine in which cell and/or tissue types CTPS1
was expressed to more fully understand how the identified CTPS1 interacting proteins could
influence CTPS1 function.
4.3.4.1 CTPS1 Expression in Rat Tissue Extract
Evidence from studies in various cell types including tumor cells has demonstrated
that CTPS activity is increased in rapidly proliferating cells suggesting that CTPS1 may not
be highly expressed in post-mitotic differentiated cells. To investigate CTPS1 protein
expression, rat tissue was harvested from an adult rat, lysed and homogenized, proteins
separated by SDS PAGE and CTPS1 was detected by immunoblotting. Unexpectedly,
CTPS1 protein expression in adult rat was highest in brain, a tissue composed of mostly post-
mitotic cells, followed by liver (Figure 4.11A). Interestingly microtubules, Pin1 and GSK3
are known to play significant roles in neurons suggesting that these proteins may regulate
CTPS1 in brain. Further studies will be needed to determine in which neuronal cell types
and brain regions CTPS1 is expressed.
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Figure 4.11 CTPS1 Expression in Rat Tissue and Cell Lines
(A) 3 grams of indicated rat tissue was homogenized in SDS RIPA lysis buffer and
clarified by centrifugation. 30 µg of protein was separated on a 4-12% gradient gel,
transferred to PVDF and immunoblotted for CTPS1. Because the contribution of proteins
(e.g. tubulin, actin) normally used to verify equal protein loading vary from tissue to tissue
with respect to the total amount of protein, they cannot be used to determine equal loading
(B) Cells were lysed in RIPA lysis buffer without SDS and lysates were clarified by
centrifugation. 30 µg of protein was separated by SDS PAGE and CTPS1 was visualized by
immunoblotting with anti-CTPS1 antibody. -actin was analyzed as a loading control.
RAW = RAW 264.7 murine macrophage cell line, RAJI = Human Burkitt’s Lymphoma cell
line, NB4 = Human Acute Promyelocytic Leukemia Cell line, HL60 = Human Myeloid
Leukemia, K562 = Human Chronic Myelogenous Leukemia, MCF7 MDR = Human Breast
Adenocarcinoma cell line-multi-drug resistant, MCF7 = Human Breast Adenocarcinoma cell
line, YF-/- = Yes and Fyn kinase knockout murine embryonic fibroblasts, SYF-/- +Src = Src,
A
B
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Yes and Fyn kinase knockout murine embryonic fibroblasts with Src retransfected back,
SYF-/- = Src, Yes, and Fyn knockout murine embryonic fibroblasts, C2C12 myoblasts =
Subclone of a murine myoblast cell, C2C12 myotubues = Differentiated C2C12 myoblasts,
3T3 L1 = Substrain of Swiss 3T3 cells, preadipocyte fibroblast-like cell line, 3T3 L1
Differentiated = 3T3 L1 induced to differentiate into adipocytes, GN4 = Rat liver epithelial
liver cells, HEK 293 = Human embryonic kidney cells.
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4.3.4.2 CTPS1 Expression in Lysates from Various Cell Lines
Investigation of CTPS1 expression of various cell types revealed that HEK 293 cells
had the highest CTPS1 expression (far higher than any other cell line tested) indicating HEK
293 cells are a good source for endogenous CTPS1 for use in biochemical studies.
Differentiation of C2C12 myoblasts to myotubes did not greatly alter CTPS1 expression.
Surprisingly, differentiation of 3T3 L1 cells into adipocytes decreased expression of CTPS1
suggesting that CTPS1 may be important in adipogenesis (Figure 4.11 B).
4.3.5 c-Myc is Involved in Regulating CTPS1 Expression
One of the transcription factors known to regulate 3T3 differentiation into adipocytes
and to regulate the transcription of another important pyrimidine biosynthetic enzyme
(CAD), is the transcription factor c-myc (Miltenberger et al., 1995; Pulverer et al., 1994). To
investigate whether c-myc was involved in the regulation of CTPS1 expression, CTPS1
protein levels was assessed by immunoblotting CTPS1 from c-myc-/- or c-myc+/+ MEFs
infected with GFP or c-Myc adenovirus in the presence or absence of serum. CTPS1 protein
expression was found to be less in the c-myc-/- cells compared to the c-myc +/+ cells and the
introduction of c-myc by viral infection into the c-myc-/- cells restored CTPS1 expression
(Figure 4.12). These results indicate that c-myc can regulate CTPS1 protein expression.
Inspection of the promoter sequence of CTPS1 revealed an E-box, c-myc binding site, -70
and -300 bps from the translational start site (See Chapter 1).
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Figure 4.12 Expression of CTPS1 in MEFs from c-myc-/-, c-myc+/+ and c-myc-/- 
(addback c-myc) Cells
The indicated MEF were infected with the indicated adenovirus and then media
switched to 10% or 0.1% FBS as described in “Experimental Procedures”. CTPS1 and -
actin was visualized as described in “Experimental Procedures”.
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4.4 Conclusion
4.4.1 Pin1 Interaction
Our data indicate that Pin1 could be a novel CTPS1 interacting protein and may
regulate CTPS1 function. Under the conditions tested, siRNA against Pin1 did not affect
CTPS1 activity indicating that if Pin1 is truly a CTPS1 interacting protein it may regulate
CTPS1 activity under conditions different from those tested or Pin1 could regulate other
aspects of CTPS1 regulation such as localization or interaction with other proteins. Attempts
to immunoprecipitate endogenous Pin1 or endogenous CTPS1 and immunoblot for the
reciprocal protein were unsuccessful despite proper immunoprecipitation of the intended
protein (data not shown). This may be dependent on the stoichiometry of S575
phosphorylation as our results demonstrated this was required for interaction. The inability
to coimmunoprecipitate Pin1 or CTPS1 may be the result of transient interaction between the
two proteins. Using a cross-linking agent may help in stabilizing the interaction allowing for
verification of this interaction among endogenous proteins. Alternatively, the interaction of
the endogenous proteins may be difficult to detect because the Pin1 and CTPS1 interaction is
a small portion of the total Pin1 or CTPS1. It is also possible that the Pin1 and CTPS1 do not
normally interact, but this seems unlikely given that the interaction depends on a known
phosphorylation site (S575) proposed to be important for phosphorylation regulation of
CTPS1 (e.g. phosho-S575 primes for GSK3 phosphorylation of S571).
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4.4.2 Tubulin Interaction with CTPS1
The tubulin interaction with CTPS1 was unanticipated and little precedent exists for
this interaction. One possible reason for this interaction is that tubulin is acting as a scaffold
protein, channeling products from one reaction to the next. One of the potentially important
tubulin interacting proteins is nucleoside diphosphate (NDP) kinase (Nickerson and Wells,
1984). NDP kinase forms UTP and GTP from UDP and GDP, respectively. Since UTP and
GTP are used by CTPS it is possible that polymerized microtubules are acting as a scaffold to
allow for more efficient shuttling of NDP products, UTP and GTP, into the CTPS reaction.
Another nucleotide enzyme, ribonucleotide reductase, is also involved in microtubule
dynamics (Takada et al., 2000) and cytoplasmic dynein, which was identified in our screen of
CTPS1 interacting proteins, can hydrolyze CTP faster than ATP (Collins and Vallee, 1989;
Shpetner et al., 1988). This further suggests that substrate channeling may be involved in the
synthesis of dCDP since CDP is a substrate for ribonucleotide reductase and cytoplasmic
dynein would efficiently generate CDP (Figure 4.13).
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Figure 4.13 Model of Substrate Channeling on Microtubules of Cytidine Nucleotides
NDP kinase can convert GDP and UDP to GTP and UTP, respectively. CTPS can
use the GTP as an allosteric activator for forming CTP from the UTP formed in the NDP
kinase reaction. Cytoplasmic dynein or NDP kinase (the affinity of CTP for NDP kinase is
low, suggesting cytoplasmic dynein as the major enzyme for the formation of CDP) can
hydrolyze CTP to form CDP. CDP is an efficient substrate for reduction by ribonucleotide
reductase, yielding dCDP, which can be phosphorylated to dCTP for use in DNA synthesis.
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4.4.3 CTPS1 Expression in Tissue and Cell Lines
The expression of CTPS1 in rat tissue revealed some unexpected findings and
indicates that CTPS1 is expressed in the brain, suggesting a role for CTPS1 in brain function.
Interestingly, the ability of CTPS1 to interact with tubulin and Pin1 and to be regulated by
GSK3 phosphorylation suggests that CTPS1 may be colocalized with these proteins in this
tissue. Furthermore, CTPS1 mRNA is expressed areas in discrete areas zebra fish embryos
that give rise to brain structures implicating a role for CTPS1 in neurological development
(http://www.zfin.org). Whether or not CTPS1 has a neuronal specific function or
dysregulation of CTPS contributes to the development of neurological disorders such as
Alzheimers, remains to be investigated.
4.4.4 CTPS1 Expression in Cell Lines
Expression of CTPS1 in cell lines revealed that HEK 293 cells highly express CTPS1
compared to the other cell lines examined. Additionally, CTPS1 protein expression levels
were decreased in 3T3 cells stimulated to differentiate into adipocytes indicating a possible
role for CTPS1 in adipogenesis.
The observation that CTPS1 protein levels decreased in differentiated 3T3 cells and
the fact that c-myc is involved in adipocyte differentiation suggested that CTPS1 may also be
regulated by c-myc. In collaboration with Eric M Wauson, we found that c-myc-/- MEFs had
decreased CTPS1 protein levels and infection with the adenovirus containing c-myc +/+
restored CTPS1 protein expression levels indicating that c-myc is involved in CTPS1
expression. Further investigation will be needed to determine whether c-myc regulates
transcription of CTPS1 directly or if the effect of c-myc on CTPS1 protein expression is
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indirect. Furthermore, it would be interesting to investigate whether reduction in CTPS1
protein expression is required for 3T3 adipocyte differentiation.
CHAPTER
5. Summary and Future Directions
5.1 Summary
CTP is an essential metabolite required for phospholipid synthesis, protein sialylation
and DNA/RNA synthesis. CTPS is a critical regulator of CTP levels in cells and CTPS
activity can affect CTP-dependent processes, such as phospholipid synthesis. CTPS can bind
four nucleotides (ATP, UTP, CTP and GTP) and the amino acid glutamine, providing
exquisite metabolite control of CTPS. In addition to metabolite control, CTPS1 in S.
cerevisiae (URA7) was found to be regulated by PKA and PKC phosphorylation. This study
investigated whether the mammalian CTPS1 is regulated by phosphorylation and if so, what
are the kinases responsible. Additionally, we identified hCTPS1 interacting proteins, which
may further our understanding of how hCTPS1 is regulated. We found that PKA and PKC
are not essential for the phosphorylation of endogenous hCTPS1. However, this result may
not be terribly surprising because regulation of nucleotide and lipid metabolism in yeast is
expected to be quite different from mammals, which require highly regulated and localized
production of these intermediates during different stages of development. Unexpectedly, we
found that endogenous hCTPS1 was phosphorylated under low-serum conditions in a GSK3-
dependent manner. S571, located in the c-terminus of hCTPS1, was identified as the major
GSK phosphorylation site and required S575 to be phosphorylated for this phosphorylation to
occur. Incubation of HEK 293 cells in low-serum reduced CTPS1 activity and inhibition of
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GSK3 prevented this decrease in CTPS1 activity, indicating that GSK3 phosphorylation of
hCTPS1 is inhibitory. Dephosphorylation of hCTPS1 in vitro with alkaline phosphatase
increased hCTPS1 activity in a time-dependent manner demonstrating that phosphorylation
of hCTPS1 is inhibitory. A large-scale analysis of phosphorylation sites in HeLa cells
identified multiple phosphorylated residues in the c-terminus of hCTPS1, many of which
were also consensus sites for phosphorylation by CK I. Inhibition of CK I demonstrated that
CK I is involved in hCTPS1 phosphorylation, but whether this is a direct phosphorylation
and which sites are phosphorylated by CK I remains to be determined. Since several GSK3
substrates (e.g. tau protein) can interact with the peptidylprolyl isomerase, Pin1, we
investigated whether Pin1 can also interact with hCTPS1. We found that Pin1 can interact
with hCTPS1 in a phosphorylation S575-dependent manner. However, reduction of Pin1
expression by siRNA did not alter hCTPS1 activity under the conditions examined,
suggesting that Pin1 may regulate a different aspect of hCTPS1 function or regulates
hCTPS1 activity under different conditions. Investigation of hCTPS1 interacting proteins
also revealed that tubulin is a hCTPS1 interacting protein. The hCTPS1/tubulin interaction
was verified by observing colocalization of the two proteins in cells and immunoprecipitation
and reciprocal immunoprecipitation of tubulin and hCTPS1. Other potential hCTPS1
interacting proteins were identified by mass spectrometry from polyacrylamide gels
containing hCTPS1 coimmunoprecipitating proteins. Further investigation will be needed to
verify these as true hCTPS1 interacting proteins. Examination of CTPS1 expression in rat
tissue demonstrated that CTPS1 was most highly expressed in the brain followed by the liver,
suggesting CTPS1 may have a brain-specific function. Expression of CTPS1 in cell-lines
showed that CTPS1 expression was significantly higher in HEK 293 cells than any other cell
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line examined. Interestingly, differentiated 3T3 cells had decreased CTPS1 protein levels
compared to undifferentiated 3T3 cells, suggesting CTPS1 may have a role in adipogenesis.
Inhibition of the transcription factor c-myc is essential for the differentiation of 3T3 L1 cells
and c-myc regulates expression of another pyrimidine biosynthetic enzyme, CAD, providing
evidence that c-myc may regulate CTPS1 expression (Pulverer et al., 1994). Using c-myc-/-,
c-myc+/+ and c-myc adenovirus we showed (in collaboration with Eric M. Wauson) c-myc is
involved in regulating CTPS1 expression. This is the first comprehensive study of
mammalian CTPS1 regulation and this data will provide a basis for future elucidation of how
this critical enzyme is regulated.
5.2 Future Directions
The identification of CTPS1 as a novel GSK3 substrate points to CTPS1 as having a
possible role in GSK3-mediated signaling pathways. GSK3 is involved in various signaling
pathways involving insulin/IGF, Wnt, hedgehog, inflammatory cytokines and motagens (for
review see (Frame and Cohen, 2001; Jope et al., 2007; Kim and Kimmel, 2000; Kim and
Kimmel, 2006)) and whether CTPS1 is involved is unexplored. To investigate the role of
CTPS1 in these pathways, CTPS1 activity will need to be measured and/or specifically
inhibited. Preliminary experiments could be done using the CTPS inhibitor, CPEC, but to
circumvent inhibition of any unintended targets of CPEC, siRNA towards CTPS1 should be
employed. Reducing CTPS1 expression using siRNA also has the advantage of specifically
targeting CTPS1 and not CTPS2, thereby allowing the different roles of the two isoforms in
the signaling pathway being investigated to be elucidated.
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In order to investigate the role of specific CTPS1 phosphorylation sites in GSK3
signaling pathways, endogenous CTPSs will need to be replaced with site-specific
phosphonull mutants. A vector that coexpresses the shRNA to reduce a target of choice
while simultaneously expressing a protein of interest has been developed and would be well
suited for investigating the role of specific phosphorylation sites in cell signaling (Vitriol et
al., 2007). To reduce the expression of endogenous CTPS1, CTPS2 or both, shRNA would
need to be designed to target the 5’ UTR, which will target endogenous mRNA but not
mRNA transcribed from the construct encoding for the protein of interest. To determine the
role of S571 phosphorylation in signaling events, expression of both CTPS isoforms will
need to be reduced and S571A mutant would be expressed from this construct. Alternatively,
the last thirty amino acids could be removed to form a carboxy-terminal CTPS1 truncation
mutant devoid of any c-terminal phosphorylation sites (CTPS1 -C-term(1-561)), which
could be introduced into cells to assess whether c-terminal phosphorylation is involved in
any GSK3-dependent signaling (e.g. Wnt, insulin, IGF, hedgehog, etc.).
A more physiological approach would be to generate tissue specific CTPS1 knockout
mice, challenge these animals with various stimuli (e.g. insulin, IGF, etc.) and measure a
physiological response such as the reduction of blood glucose levels following insulin
treatment. Based on our observations of the unique regulation of CTPS1, and other enzymes
and on the unique tissue localization of CTPS1 we predict that CTPS1 knockouts will have
important developmental defects.
GSK3 can bind to Axin and FRAT scaffold proteins (Frequently Rearranged in
Advanced T cell lymphomas ), which can affect GSK3 substrate phosphorylation. To
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determine whether CTPS1 is also part of the Axin or FRAT complex, CTPS1 could be
immunoprecipitated and Axin or FRAT could be examined in the immunecomplex by
immunoblot analysis. Alternatively and to verify any interaction observed from the CTPS1
immunoprecipitation, Axin or FRAT could be immunoprecipitated and CTPS1 could be
detected by immunoblot analysis.
The significance of the Pin1 interaction is not yet clear. It is possible that this is an
artifact, although our data clearly demonstrates S575 phosphorylation specific binding. One
possible explanation for not observing a strong endogenous Pin1/CTPS1 interaction in HEK
293 cells is that Pin1 is mainly localized to the nucleus as where CTPS1 is mainly localized
to the cytoplasm in HEK 293 cells. Since Pin1 catalyzes the cis-trans isomerization we can
speculate that this interaction may influence the dynamics of
phosphorylation/dephosphorylation of this protein. Thus Pin1 may provide an additional
level of regulation to this complex mechanism.
The GSK3 phosphorylation site (S571) identified in CTPS1 was already mutated in a
cell line from retinitis pigmentosa suggesting GSK3 and/or CTPS1 may be involved in
retinitis pigmentosa. Several studies of retinitis pigmentosa have found components of the
Wnt signaling pathway, which requires GSK3, aberrantly regulated (Jones et al., 2000a;
Jones et al., 2000b; Pauer et al., 2005). Interestingly, a study of genetic mutations in the
retinitis pigmentosa 1 protein found a threonine mutated to an isoleucine and the threonine is
a consensus site for phosphorylation by GSK3 (Khaliq et al., 2005). Furthermore, inspection
of the phosphorylation site database, Phosida (http://www.phosida.com), revealed two
phosphorylation sites (S582 and S583) in retinitis pigmentosa-1-like protein splice isoform 1
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(Q8IWN7, Swiss-Prot entry numbering). S582 is a consensus phosphorylation site for GSK3
and S583 is a consensus phosphorylation site for CK I (Olsen et al., 2006). To assess
whether CTPS1 and/or GSK3 are involved in eye diseases such as retinitis pigmentosa,
various mutants (e.g. CTPS1 phosphorylation site mutants or GSK3 activity mutants) can be
introduced by in vivo electroporation and their expression controlled by 4-hydroxytamoxifen
(Matsuda and Cepko, 2007). Since retinitis pigmentosa is due to the loss of photoreceptor
cells by apoptosis, the death of these cells can be used to monitor the effects of the expressed
protein. One possibility is that an imbalance in CTP synthesis and/or lipid synthesis may
promote increased apoptosis of these cells.
The expression of CTPS1 in the brain, the evidence that GSK3 regulates CTPS1
activity and Pin1 and tubulin interact with CTPS1 suggests that CTPS1 may be involved in
neurodegenerative diseases such as Alzheimer’s. To investigate the potential role of CTPS1
in neurodegenerative diseases, the CTPS inhibitor, CPEC could be used with animal models
that recapitulate the tauopathy observed in Alzheimer’s disease and determine whether
inhibition of CTPS1 decreases symptoms or the pathology associated with the disease.
Additionally, nucleotide and/or phospholipid levels could be measured in animal models of
Alzheimers or other neurodegenerative disorders. Expression of the mRNA of CTPS1 and
CTPS2 in murine brain as determined by the Allen Institue (http://www.brainmap.org)
demonstrated that both CTPSs are expressed in the cortex, cerebellum and hippocampus.
The expression in the hippocampus suggests that CTPS may be involved in learning and
memory. The brain region expression of CTPS1 in developing zebra fish
(http://www.zfin.org) suggests that CTPS1 may be involved in brain development. To
investigate the possibility that CTPS1 phosphorylation of CTPS1 is involved in brain
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development, phosphorylation site mutants or CTPS1 -C-term(1-561) could be introduced
into developing mouse fetuses by electroporation as done previously by Dr. Franck Polleux
in the department of pharmacology at the University of North Carolina at Chapel Hill. It will
also be important to characterize the phosphorylation of CTPS (S571) during development.
According to a model involving GSK3 regulation by Wnt and CTPS phosphorylation this site
may be an important marker of CTPS regulation during this time.
In order to map the CK I phosphorylation sites in CTPS1, it would be a good idea to
start by investigating if the existing phosphonull mutations of CTPS1 inhibit CK I
phosphorylation in vitro. A panel of recombinant CK I isoforms (, , 1, 2, 3,  and )
could be used to phosphorylate CTPS1 in vitro to determine which CK I isoform is the most
efficient kinase for phosphorylating CTPS1. Preliminary results using IC261, which more
specifically inhibits CK I  and , suggests that these isoforms are not involved in the
phosphorylation of CTPS1 (Matthew J Higgins, unpublished observations). Since CK I
enzymes are considered to be constitutively active, it would be difficult to stimulate CK I and
determine whether a particular potential CTPS1 phosphorylation site mutation (e.g. S571A)
alters CTPS1 phosphorylation. However, CK I enzymes seem to be regulated by protein
expression and localization, which could be used to target the activation or inhibition of
certain CK I isoforms in intact cells. What could be done is to use isoform-specific siRNA to
reduce protein expression of a particular CK I isoform and then analyze the 2D
phosphopeptide maps of CTPS1 for differences. This however requires a siRNA that will
inhibit expression of the CK I isoform of interest or knowledge of which CK I isoform is
responsible for phosphorylating CTPS1. The best CK I inhibitor is D4476, but even this
inhibitor may not be very effective in inhibiting CK I or the CK I isoform predominantly
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responsible for phosphorylating CTPS1 and this will interfere with the ability to understand
how CK I affects CTPS1 function. Therefore, a strategy using siRNA should be employed to
overcome this problem. However, it should be noted that if multiple CK I isoforms
phosphorylate CTPS1, inhibiting one isoform may not affect CTPS1 phosphorylation due to
compensatory phosphorylation by another CK I isoform. Should CK I isoforms compensate
for each other, a siRNA strategy (or analogous strategy) to target all CK I isoforms should be
employed. Another means to identify which CK I isoform is involved in phosphorylating
CTPS1 would be to immunoprecipitate CTPS1 and immunoblot for the various CK I
isoforms to determine if a particular CK I isoform coimmunoprecipitates with CTPS1.
One possible mechanism for how CK I might affect CTPS1 function is by modulating
the sensitivity of CTPS1 to inhibition by GSK3. To investigate this CTPS1 activity should
be measured from untreated CTPS1 or CK I phosphorylated CTPS1 followed by incubation
with GSK3 for various times. Should CK I modulate GSK3 inhibition of CTPS1, the
prephosphorylation of CTPS1 by CK I would alter the time observed for GSK3 to alter
CTPS1 activity.
Identification of the kinase responsible for phosphorylating S575 has eluded this
investigation. Since S575 is followed by a proline, it is most likely phosphorylated by a
proline-directed kinase, such as cyclin-dependent kinases (CDKs) or mitogen-activated
protein kinases (MAPKs). The phosphorylation of CTPS1 was not altered in HeLa cells
synchronized by double-thymidine block and phosphorylation of CTPS1 was not altered by
the CDK inhibitors roscovitine or olomoucine, indicating that CDKs under the conditions
tested were not involved in the phosphorylation of CTPS1. There is a possible cyclin binding
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site in CTPS1 that could be mutated that would abrogate targeting of any CDKs to CTPS1
and thereby confirm or deny the role of CDKs in CTPS1 phosphorylation. The brain
expression of CTPS1 suggests that maybe CDK5, a neuronal specific CDK, is involved in
phosphorylating CTPS1. Olomoucine can inhibit CDK5 with the p35 cyclin binding partner
suggesting that CDK5p35 is probably not the kinase involved, but the olomoucine study was
done in HEK 293 cells where CDK5 is probably not highly expressed. Repeating this
experiment in a cell type where CDK5 is expressed should be done to confirm or deny the
role of CDK5 in the phosphorylation of CTPS1. Since CDK5 can use other cyclin binding
partners, it is possible that CDK5 with a different cyclin binding partner is involved in
phosphorylating CTPS1. Another CDK to investigate would be p34CDK4/cyclin D and
p40CDK6/cyclin D3 since these CDKs were not sensitive to the CDK inhibitors used in this
study (olomoucine).
Activation or inhibition of the MAPKs, JNK and ERK, did not alter CTPS1
phosphorylation indicating these kinase are not likely to be involved in CTPS1
phosphorylation. Inhibition of the other major MAPK, p38, with SB202190 did not alter
CTPS1 phosphorylation (Matthew J Higgins, unpublished observation) suggesting that p38 is
not involved in the phosphorylation of CTPS1 under the conditions examined.
A less biased means of identifying the kinase responsible for phosphorylating S575
would be to fractionate cell lysate on an ion-exchange column and use the fractions in an in
vitro kinase reaction with a WT GST-c-term or S575A GST-c-term CTPS1 as substrates.
Ideally, this would be done with lysate where GSK3 activity has been eliminated since
phosphorylation of S571 depends on phosphorylation of S575. The proteins in the fraction
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showing specificity for phosphorylating S575 could be separated by SDS PAGE (or even
two-dimensional SDS PAGE) and identified by mass spectrometry. Additionally, the ion-
exchange fraction containing the S575 kinase could be further purified by passing the
fraction over an ATP affinity column and then subjecting the ATP affinity-bound proteins to
SDS PAGE for identification by mass spectrometry. Alternatively, kinases could be
identified on SDS-PAGE by performing an in-gel kinase reaction with the column fractions.
Tubulin and CTPS1 were found to be in a complex with each other. To investigate
whether tubulin is a scaffold for pyrimidine biosynthesis, all the proteins proposed to be
associated with tubulin should be verified by polymerizing tubulin and determining if these
proteins (NDP kinase, CTPS1, cytoplasmic dynein, ribonucleotide reductase) are associated
with the polymerized tubulin. Since we propose tubulin is a scaffold for some of the
pyrimidine metabolizing enzymes allowing for more efficient shuttling of the product from
one reaction to the next enzyme, it would be interesting if this could be recapitulated in vitro.
One way to do this would be to isolate crude lysate (100,000 x g centrifugation), incubate
[14C]UDP in the presence of taxol-stimulated polymerized microtubules or unpolymerized
microtubules and measure by HPLC or TLC the formation of other nucleotides (e.g CTP,
CDP, dCDP, UTP, UDP).
To identify the region(s) of CTPS1 needed for the tubulin interaction, Flag tagged
truncation mutants corresponding to various regions of CTPS1 (e.g. amidoligase domain,
glutamine amidotransferase domain) could be constructed. To determine whether tubulin
interacts with the CTPS1 truncation mutants, CTPS1 could be immunoprecipitated and the
coimmunoprecipitation of tubulin could be monitored by immunoblot. Reciprocally, tubulin
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could be immunoprecipitated and the Flag-tagged CTPS1 fragment be monitored via
immunoblot using the -Flag antibody. Results from coimmunoprecipitation experiments
could be confirmed by immunostaining the CTPS1 fragment with -Flag antibody and
immunostaining tubulin in HEK293 cells. Fluorescent energy transfer (FRET) could also be
used to monitor the tubulin/CTPS1 interaction in live cells. A CFP-CTPS1 has already been
made by David Brown and HeLa cells stably expressing YFP-tubulin have already been
selected for (Matthew J Higgins). CFP-CTPS1 truncation mutants could be used to
determine whether the tubulin/CTPS1 interaction depends on certain regions of CTPS1 in
intact cells.
An interesting possibility is that phosphorylation modulates the interaction with
CTPS1 interacting proteins such as tubulin. To investigate this possibility various
phosphorylation site mutants (e.g. S571I, S574A, S575A, CTPS1 -C-term(1-561),
etc).should be transfected and whether tubulin coimmunoprecipitation is affected by the
mutant could be assessed by immunoblot. Alternatively, to determine whether CTPS1
phosphorylation affects the tubulin/CTPS1 interaction the phosphorylation of CTPS1 could
be inhibited using GSK3 inhibitors and/or CK I inhibitors and the coimmunoprecipitation of
tubulin monitored by immunoblot.
In addition to tubulin, several other potential CTPS1 interacting proteins were
identified. To further verify that these other possible hCTPS1 interacting proteins can
specifically form a complex with CTPS1, these potential CTPS1 interacting proteins should
be probed for from immunoprecipitated CTPS1 using specific antibodies directed towards
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the protein of interest. If an antibody does not exist for the protein of interest, then a tagged
version of the protein can be expressed and the tag visualized by immunoblot.
As mentioned in chapter 3, the regulation of CTPS1 by phosphorylation may be
coordinately regulated with the phosphorylation regulation of other CTP-requiring
biosynthetic enzymes. The rate-limiting step in phosphatidylcholine biosynthesis, CCT, is
also heavily phosphorylated on its c-terminus and phosphorylation negatively regulates this
enzyme. To assess whether GSK3 can regulate phospholipid synthesis, phospholipids could
be measured by TLC from cells maintained in the presence or the absence of a GSK3
inhibitor. Additionally, we would like to identify which sialylated proteins are most sensitive
to CTP levels. To investigate this we will first radiolabel cells with [6-3H]N-Acetyl-D-
mannosamine ([3H]ManNAc) an obligate precursor for sialylation of proteins, then treat cells
with and without CPEC. Proteins will be separated on two dimensional gels. Gels will be
Coomassie stained, dried using acetate paper and visualized by autoradiography or
phosphorimager. Protein spots observed by autoradiography or phosporimager to change
with CPEC treatment will be excised and identified by mass spectrometry
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